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O Vírus da Imunodeficiência Humana do tipo 2 (HIV-2) foi identificado pela primeira vez 
como agente causal da Síndrome de Imunodeficiência Adquirida (SIDA) em 1986 numa 
colaboração entre cientistas e clínicos portugueses (Professora Maria Odette Santos Ferreira 
da Faculdade de Farmácia de Lisboa e Professor José Luís Champalimaud do Hospital Egas 
Moniz) e franceses (equipe de investigadores liderada pelo Professor Luc Montagnier do 
Instituto Pasteur em Paris). Embora este vírus seja semelhante ao HIV-1 em termos de 
organização estrutural e genómica, muitos aspectos distinguem as infecções provocadas por 
estes dois vírus. O HIV-2 é apenas responsável por pequenas epidemias nos países onde teve 
origem e em países vizinhos ou com relações históricas com estas regiões, em oposição ao 
HIV-1 que é responsável pela pandemia mundial. A maioria dos indivíduos infectados com 
HIV-2 apresenta cargas virais indetectáveis, contagem normais de células T CD4+ e ausência 
de progressão clínica. A resposta imunitária do hospedeiro ao HIV-2 também parece ser 
melhor comparativamente ao HIV-1, uma vez que a maioria dos indivíduos mantém fortes 
respostas celulares e humorais contra o vírus durante a fase crónica da infecção por HIV-2. 
Conhecer e compreender as interacções vírus-hospedeiro na infecção por HIV-2 poderá ser 
importante no desenho de vacinas, uma vez que as respostas imunitárias geradas contra o 
HIV-2 poderão ser mimetizadas na vacinação não só contra este vírus mas também contra o 
HIV-1.  
 
Uma das maiores diferenças entre as duas infecções é a produção de anticorpos 
neutralizantes de elevado espectro e potência nos indivíduos infectados por HIV-2. Estes 
anticorpos e outras respostas imunitárias poderão ser fundamentais no controlo da infecção 
e a base para a progressão mais lenta para SIDA observada nestes doentes. Contudo, muitos 
aspectos da infecção por HIV-2 permanecem por esclarecer, nomeadamente como é que os 
anticorpos neutralizantes controlam o vírus e como o vírus reage a estes anticorpos, em 
particular na infecção aguda. Perante este cenário, o objectivo geral desta tese foi conhecer 
melhor a resposta dos anticorpos neutralizantes na infecção por HIV-2 e explorar a forma 





A forma como o hospedeiro reage ao primeiro contacto com um agente infeccioso poderá 
ser determinante para o controlo e evolução da infecção. Desta forma, estudar a infecção 
primária por HIV-2 poderá elucidar sobre quais os mecanismos envolvidos no melhor 
controlo deste vírus comparativamente ao HIV-1. Uma vez que a maioria dos doentes 
infectados com HIV-2 são apenas diagnosticados na fase crónica da infecção, muito depois 
da seroconversão, torna-se extremamente difícil estudar a infecção aguda. Devido a este 
facto, ao contrário do que se passa na infecção por HIV-1, nada se sabe sobre a resposta 
imunitária e a evolução viral na infecção aguda por HIV-2. Esta lacuna no conhecimento 
sobre a infecção por HIV-2 levou ao primeiro objectivo desta dissertação: caracterizar a 
resposta em anticorpos neutralizantes e a evolução molecular e fenotípica do HIV-2 desde as 
fases iniciais e ao longo da infecção (capítulo 3). Estudar crianças infectadas por transmissão 
vertical constitui uma oportunidade única para conhecer a infecção aguda por HIV-2. Apesar 
de ser um evento raro, existem casos documentados de transmissão mãe-filho de HIV-2. 
Foram colhidas à nascença e ao longo de vários anos amostras de sangue de duas crianças 
nascidas de mães infectadas com HIV-2. A criança 1, nascida em 1998, foi diagnosticada com 
HIV-2, por PCR, aos 39 dias de vida e a criança 2, nascida em 1992, aos 27 dias de vida. A 
criança 1 nasceu com contagens de células T CD4+ normais e ausência de viremia, mas aos 
cinco anos de idade ocorreu um aumento drástico na carga viral em paralelo com o declínio 
das células T CD4+. Iniciou-se o tratamento, o que levou à recuperação virológica e 
imunológica. A criança 2 nasceu com encefalopatia apesar ter contagens de células T CD4+ 
normais e ausência de viremia. O tratamento foi iniciado de imediato, no entanto as opções 
terapêuticas existentes nessa altura (1992) eram muito limitadas. A carga viral aumentou e 
as células T CD4+ diminuíram, acabando a criança por falecer aos 9 anos. Foi extraído DNA de 
células de final de cultura de ambas as crianças de vários anos de infecção. O gene env foi 
amplificado, clonado e sequenciado. As sequências geradas foram analisadas em termos de 
diversidade genética, pressão selectiva, taxa de evolução nucleotídica e locais de 
glicosilação. Igualmente a partir das sequências geraram-se modelos estruturais da 
glicoproteina Env por homology modelling. Determinou-se o tropismo viral dos vírus de 




neutralização com os plasmas das crianças dos vários anos de infecção contra os seus vírus 
autólogos e, no caso da criança 1, também contra 5 vírus heterólogos, três R5 e dois X4. A 
diversidade nucleotídica e aminoacídica e os locais sobre selecção positiva foram 
significativamente maiores na criança 1 comparativamente à criança 2. Da mesma forma, a 
taxa de evolução viral na criança 1 foi quase o dobro da criança 2 e semelhante à taxa de 
evolução viral em indivíduos com infecção crónica por HIV-2 a fazerem tratamento 
antirretroviral, de onde se conclui que a rápida evolução molecular do HIV-2 começa logo no 
início da infecção. Ambas as crianças foram infectadas com vírus que utilizavam o co-
receptor CCR5 (vírus R5) mas aos 5 anos de idade já possuíam vírus com tropismo para 
células exprimindo o co-receptor CXCR4 (vírus X4). Este foi o primeiro estudo em que se 
observou efectivamente uma alteração de tropismo R5 para X4 na infecção por HIV-2. De 
salientar que a transição de tropismo observada nestas crianças foi extremamente rápida, 
uma vez que vírus HIV-2 que utilizam o co-receptor X4 são geralmente encontrados em 
indivíduos infectados há vários anos e em fases avançadas da infecção. Desde o início de 
vida, a criança 1 apresentou uma forte resposta em anticorpos neutralizantes, tanto 
autóloga como heteróloga, particularmente contra vírus R5. A resposta contra vírus X4 foi 
significativamente mais fraca e diminuiu ao longo da infecção concomitantemente com o 
aparecimento das estirpes utilizadoras do co-receptor X4. A criança 2 desenvolveu uma 
resposta muito fraca contra vírus X4 autólogos, que decresceu rapidamente com a 
progressão da doença. Em ambas as crianças, a alteração no tropismo de R5 para X4, a 
diversificação das regiões V1 e V3 e a conversão da estrutura secundária da região V3 para 
conformação em β-hairpin foram associadas ao escape aos anticorpos neutralizantes. Os 
resultados indicam que na presença de uma forte resposta dos anticorpos neutralizantes 
(criança 1) a diversidade e a taxa de evolução viral são muito elevadas, ao passo que quando 
a pressão imposta pelos anticorpos neutralizantes é menor (criança 2) estes marcadores de 
evolução são semelhantes à infecção aguda por HIV-1 (tanto adultos como crianças). 
Concluindo, estes dados apoiam a hipótese de os anticorpos neutralizantes serem 





A produção de anticorpos neutralizantes está a cargo das células B. Após encontro com um 
antigénio, as células B naïve sofrem maturação e diferenciação em plasmócitos e células B 
de memória, capazes de produzir anticorpos específicos contra esse antigénio. Na infecção 
por HIV-1 e HIV-2 há diminuição acentuada do número de células B de memória. Esta 
depleção é irreversível mesmo com terapia antirretroviral. No entanto, e contrariamente à 
infecção por HIV-1, a maioria dos indivíduos infectados com HIV-2 produzem anticorpos 
neutralizantes durante a fase crónica da infecção. Qual será a relação entre as células B de 
memória e a produção de anticorpos neutralizantes na infecção por HIV-2? Conhecer, nesta 
infecção, qual a população de células B responsável pela produção dos elevados níveis de 
anticorpos neutralizantes poderá ser importante para a produção de uma vacina contra o 
HIV-1 e o HIV-2. Neste contexto, o segundo objectivo desta tese foi investigar a associação 
entre a resposta em anticorpos neutralizantes e as células B de memória na infecção por 
HIV-2 (capítulo 4). Foram estudados 37 indivíduos infectados com HIV-2, 73% dos quais 
nunca tinham recebido tratamento antiretroviral, 76% tinham carga viral indetectável e 59% 
tinham contagem de células T CD4+ igual ou superior a 350 células/µl. Os doentes 
apresentavam níveis variados de depleção das células B de memória sem alteração de classe 
(CD19+CD27+IgD+) e com alteração de classe (CD19+CD27+IgD-) directamente associada à 
diminuição do número de células T CD4+. Conhecia-se igualmente a resposta em anticorpos 
de ligação contra as regiões C2V3C3 e gp36 do invólucro. Os ensaios de neutralização foram 
efectuados com os plasmas dos indivíduos em estudo contra quatro vírus R5 heterólogos. 
Verificou-se que todos os doentes produziam anticorpos neutralizantes de elevada potência. 
Estes anticorpos eram também de largo espectro uma vez que, com duas excepções, todos 
os plasmas neutralizavam pelo menos dois vírus (55% neutralizavam três ou quatro vírus). O 
título de anticorpos neutralizantes não estava associado à contagem de células T CD4+, à 
carga viral ou ao tratamento antirretroviral. Contudo, o título de anticorpos neutralizantes 
estava associado ao nível de anticorpos de ligação contra a região C2V3C3 nos doentes com 
contagem de células T CD4+ ≥ a 350 células/µl, e aos anticorpos de ligação contra a região 
gp36 em doentes em estados mais avançados da doença (células T CD4+ < 350 células/ µl). 
Além disso, o título de anticorpos neutralizantes estava inversamente associado à depleção 




Os resultados obtidos sugerem que, apesar da diminuição das células B de memória com a 
progressão da doença, continuam a ser produzidos anticorpos neutralizantes de elevado 
espectro e potência ao longo da infecção por HIV-2. Estudos recentes com o HIV-1 
mostraram que, apesar de serem raros os doentes que produzem anticorpos neutralizantes, 
a produção de anticorpos não específicos é mantida pelos plasmócitos, que não necessitam 
de constante exposição ao antigénio para produzirem anticorpos. Os resultados 
apresentados nesta tese apontam para que outra população de células B (provavelmente os 
plasmócitos) seja responsável pela produção e perpetuação dos anticorpos na infecção por 
HIV-2, com a principal diferença, face ao HIV-1, destes serem neutralizantes. Estes 
anticorpos são maioritariamente dirigidos contra a região C2V3C3 e, em fases mais 
avançadas da infecção, contra a gp36.  
 
Estudos recentes verificaram que vírus HIV-2 com tropismo para células que expressam o 
coreceptor CXCR4, isolados de doentes a fases avançadas da infecção, são resistentes aos 
anticorpos neutralizantes. Foi também descrito no Capítulo 3 que vírus X4 isolados de 
crianças recentemente infectados são mais resistentes à neutralização. Estes resultados 
sugerem uma associação entre escape aos anticorpos neutralizantes e alteração de tropismo 
de R5 para X4. No entanto, permanece a dúvida se os vírus com tropismo para X4 são 
intrinsecamente resistentes à resposta em anticorpos neutralizantes. O terceiro objective 
deste trabalho foi caracterizar o fenótipo de neutralização de isolados primários utilizadores 
do coreceptor X4 isolados de doentes infectados com HIV-2 em várias fases da infecção de 
forma a determinar se todas as estirpes X4 são resistentes aos anticorpos neutralizantes 
independentemente do estadio da doença. Foram estudados cinco vírus X4 isolados de 
doentes em estados avançados de doença (mediana de células T CD4+=78 células/μl) e dois 
vírus X4 isolados de crianças infectadas por transmissão vertical (ver capítulo 3) em fase 
inicial da infecção (5 anos) (mediana de células T CD4+=320 células/μl). A sensibilidade dos 
vírus X4 à neutralização foi comparada com três vírus R5 usados como controlo (mediana de 
células T CD4+=275 células/μl). Os ensaios de neutralização foram efectuados contra 16 
isolados clínicos heterólogos. Observou-se que os vírus X4 eram significativamente mais 




foram isolados. O facto de os vírus X4 das crianças serem também mais resistentes à 
neutralização que os vírus R5, demonstra que a resistência aos anticorpos neutralizantes 
pode surgir muito cedo após a transmissão. Além disso, os vírus X4 de indivíduos em estados 
avançados de doença eram significativamente mais resistentes aos anticorpos neutralizantes 
que os vírus X4 isolados das crianças (infecção recente), o que sugere que a resistência aos 
anticorpos neutralizantes é um processo gradual que vai ocorrendo ao longo da infecção. Ao 
analisar-se a região V3 dos vírus em estudo, detectou-se que todos os vírus X4 apresentavam 
as mutações nesta região anteriormente associadas a alteração de tropismo de R5 para X4 
(uma mutação na posição 18, a mutação V19K/R, uma inserção na posição 24 e uma carga 
global igual ou superior a 7). A avaliação das estruturas secundárias desta região revelou 
igualmente diferenças importantes entre vírus R5 e X4. Os vírus R5 na infecção aguda e 
crónica são caracterizados por ausência de estrutura secundária regular, ao passo que os 
vírus X4 de infecção recente apresentam uma estrutura secundária em β-hairpin. Os vírus X4 
de indivíduos em fase avançada caracterizam-se pelas conformações β-α-β ou helix-loop-
helix. Estes dados sugerem um modelo de evolução da estrutura secundária da região V3 no 
qual, ao longo da infecção, a pressão exercida pelos anticorpos neutralizantes sobre a V3 
força o vírus a escapar e a alterar esta região de forma que deixe de ser reconhecida pelos 
anticorpos neutralizantes. Estas alterações favorecem igualmente a mudança de tropismo 
para X4 o que por sua vez está associado ao decréscimo das células T CD4+. Estes dados 
mostram que a resistência aos anticorpos neutralizantes é uma característica intrínseca dos 
vírus X4, provavelmente determinada por alterações na sequência e conformação da região 
V3, que dificultam o reconhecimento desta região pelos anticorpos. 
 
Em conclusão, este trabalho permitiu demonstrar que a resposta dos anticorpos 
neutralizantes surge muito cedo na infecção aguda e persiste na fase crónica da infecção 
mesmo após significativa depleção das células B de memória, e ainda que os Nabs são 
responsáveis pela evolução viral, por alterações estruturais na região V3 e pela alteração do 
tropismo que leva à resistência à neutralização. Os resultados constituem também um novo 
e potencialmente relevante contributo na área das vacinas. Em primeira análise, o escape à 




vacina necessita de geral respostas contra estirpes R5 e X4. Os anticorpos são 
principalmente dirigidos contra a região V3 nas fases inicial e crónica da infecção. Em 
estádios mais avançados, a resposta contra esta região diminui mas surgem anticorpos cujo 
alvo é a gp36. Estes resultados confirmam que a V3 é um bom imunogénio a ser usado no 
desenho de vacinas mas salientam o facto de a gp36 poder conter epitopos importantes a 
serem incluídos numa vacina. Outra importante contribuição destes estudos foi a descoberta 
de que é possível manter uma forte resposta em anticorpos neutralizantes através de 
populações de células B que não as de memória, nomeadamente plasmócitos. Uma vacina 
contra o HIV-2 e o HIV-1 idealmente estimularia respostas deste tipo de células B. A 
dificuldade persiste em escolher o imunogénio ou grupo de imunogénios capazes de suscitar 
estas respostas. Destes estudos conclui-se que imunogénios baseados na região V3 e na 















Dynamics of the neutralizing antibody response and resulting HIV-2 escape during acute and 
chronic infections and their impact on viral evolution and disease progression remain 
unknown. The aims of this thesis were: characterize Nab response and molecular and 
phenotypic evolution of HIV-2 in early infection, investigate Nab responses in HIV-2 
chronically infected patients with memory B cell imbalances and characterize the 
neutralization phenotype of HIV-2 X4-tropic isolates from diverse disease stages. 
Broad and potent Nabs are elicited very early in HIV-2 infection, the potency of this response 
being associated with high evolutionary rates. Nab escape was associated with R5-to-X4 
switch, increased diversity in V1 and V3 regions and changes in V3 conformation. These 
findings show that Nabs are the main driver of the rapid molecular and phenotypic evolution 
of HIV-2 in early infection. 
Despite the loss of memory B cells observed with disease progression, broad and potent 
Nabs were elicited throughout HIV-2 infection. Nabs were found to target the C2V3C3 
envelope region and, in advanced disease stage, the gp36 ectodomain. These data suggest a 
role for other B cell subsets in the production and perpetuation of Nabs. 
HIV-2 X4-tropic viruses were found to be significantly more Nab resistant than R5 viruses 
(independently of disease stage) and late infection X4 isolates were significantly more Nab 
resistant than early infection X4 viruses. X4-tropism was associated with sequence changes 
and significant gain in the V3 loop secondary structure. The results prove that Nab resistance 
is an intrinsic feature of X4-tropic HIV-2 isolates, acquired through infection period, and is 
associated with amino acid and conformational changes in the V3 loop that favour R5-to-X4 
switch. 
In conclusion, Nab responses emerge very early in infection, persist despite memory B cells 















0C Celsius degree 
ADCC Antibody-dependent cell-mediated cytotoxicity 
ADCMI Antibody-dependent complement-mediated inactivation 
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The origin and discovery of the Human Immunodeficiency Virus 
type 2 (HIV-2) 
 
Immunodeficiency viruses, belonging to the Lentivirus genus, can be found in several species 
including non-human primates [1, 2]. These simians are the natural reservoir of many 
different specific variants of Simian Immunodeficiency Virus (SIV). Several independent 
zoonotic transmission events lead to the introduction of these viruses to humans. Human 
Immunodeficiency Virus type 1 (HIV-1) was introduced to humans from SIVcpz that infects 
West Central African chimpanzees (Pan troglodytes troglodytes) and from SIVgor that infects 
Western lowland gorillas (Gorilla gorilla gorilla) [1-6]. HIV-2 is closely related to SIVsm which 
is found in sooty mangabey monkeys (Cercocebus atys atys) [7, 8]. Phylogenetic analysis 
shows that there have been many cross-species transmissions to humans, with each 
successful event resulting in a specific form (group) of HIV [1, 9, 10]. In HIV-2 transmission 
events are thought to be at least eight, giving rise to groups A to H [8, 11], whereas in HIV-1 
tree cross-species events occurred from chimpanzees to humans (groups M, N and O) [12, 
13], and one from gorillas (group P) [5, 6]. Transmission from simians to man is estimated to 
have occurred in the late nineteenth through early twentieth century but its consequences 
have only be detected in 1981 for HIV-1 and 1985 for HIV-2 [14-16]. Indeed, the Acquired 
Immunodeficiency Syndrome (AIDS) was first described in 1981 in the United States of 
America (USA), after the observation of opportunistic infections along with immune 
suppression in young men who have sex with men (MSM) in New York City and California 
[17, 18]. Soon after similar observations were made in patients from Haiti, Africa and Europe 
[19-21] and it became clear that the new disease with unknown cause struck also 
haemophiliacs, injection drug users (IDU), women and infants (mother to child transmission - 
MTCT) [22-25]. In May 1983, at the Pasteur Institute (Paris), Luc Montagnier and Françoise 
Barré-Sinoussi isolated a new retrovirus from an AIDS patient [26] and in the following year a 
similar retrovirus was isolated by American investigators [27]. These findings proved that 
this retrovirus, later classified as HIV-1, was the causative agent of AIDS [28].  
In the early 80’s, patients from Guinea-Bissau and Cape Verde Islands were admitted in a 




but with constant negative serologic tests. At the time Maria Odette Santos Ferreira from 
the Faculty of Pharmacy of Lisbon took the blood samples from these patients to Luc 
Montagnier at the Pasteur Institute (Paris). The collaboration between Portuguese and 
French researchers lead to the characterization of a second retrovirus, distinct from HIV-1, 
classified as HIV-2 [29-31]. 
 
The global spread of HIV-2 
 
According to UNAIDS, globally there has been a decline the number of newly infected adults 
and children in the last 10 years [32]. With the scale up of antiretroviral therapy (ART) over 
the past few years, the number of AIDS-related deaths has also decreased, but with the 
significant reductions in mortality the number of people living with HIV worldwide has 
increased. By the end of 2011, there were an estimated 34 million people living with HIV, 2.5 
million newly infected adults and children and 1.7 million AIDS-related deaths [32]. Sub-
Saharan Africa still accounts for the highest HIV burden, with 69% of the total number of HIV 
infected individuals and an average prevalence among adults of 4.9%. However, in 23 Sub-
Saharan countries, the incidence of HIV has decreased more than 25% [32].  
Despite the existence of eight HIV-2 groups, only groups A (HIV-2A) and B (HIV-2B) are 
considered endemic, with group A frequently found in the western part of West Africa 
(Guinea-Bissau, Senegal, The Gambia, Ivory Coast and Cape Verde)  and group B more 
restricted to Ivory Coast and Ghana [11, 29, 33-38]. The remaining groups have only been 
identified in a few individuals from Sierra Leone, Liberia and Ivory Coast [7, 39-45]. The first 
HIV-2 A/B recombinant was isolated from a patient from Ivory Coast and recently three 
other A/B recombinants have been described in Japan, which lead to the classification of the 
first circulating recombination form (CRF) of HIV-2, the HIV-2 CRF01_AB [43, 46, 47]. 
Besides its confined geography, recent reports indicate that HIV-2 prevalence is now 
decreasing even in countries where the number of cases used to be high [48-52]. For 
instance, in Guinea-Bissau the prevalence of HIV-2 decreased from 8.3% in 1990 to 4.7% in 
2007, and in The Gambia it decreased from 7.0% in 1988-91 to 4.0% in 2001-03. The 




The origins of HIV-2 groups A and B are estimated to be around 1938 and 1945, respectively 
[15, 16, 53]. The epicentre of the HIV-2B epidemic is most likely Ivory Coast, whereas some 
doubts remain about the region where the cross-species event took place for HIV-2A. There 
is strong phylogenetic evidence that trace both Ivory Coast and Guinea-Bissau as the 
epidemic centres: serologic data tends to favour Guinea-Bissau, but the recent discovery of 
SIVsmm strains closely related to HIV-2A in faecal samples from sooty mangabeys in Ivory 
Coast suggests that this region is also the epicentre of HIV-2A [8, 49, 53, 54]. Whether the 
cross-species event took place in Ivory Coast and Guinea-Bissau was where the epidemic was 
established very early after transmission or Guinea-Bissau is indeed the epicentre of HIV-2A 
remains to be clarified [8, 53, 55]. From these two countries, or because of commercial 
relations, sex trade and migration between them, HIV-2A spread to other countries in West 
Africa, like Senegal, The Gambia, Cape Verde, Nigeria and Burkina Faso [53]. The viral 
migration outside West Africa most likely happened through immigration and socio 
economic connections with high-prevalence countries. For instance, past relations between 
France and Ivory Coast and Senegal led to multiple viral introductions in France. 
Furthermore, HIV-2A is thought to have spread from Guinea-Bissau and Cape Verde to 
Portugal, mainly during the independence war [15, 53, 56]. Within Europe, strong evidences 
point to transmission from Portugal to the main immigration destinations, like Luxemburg 
and the United Kingdom (UK), but most likely to Switzerland, Belgium and Germany as well 
[53, 56]. Portugal is also thought to be responsible for transmitting HIV-2A outside of Europe 
to other countries with socio economically linkage such as India, Mozambique and Brazil [11, 
50, 57, 58].  
Portugal is one of the few countries outside West Africa with a significant number of HIV-2 
cases. In December 2011 the total number of AIDS cases associated with HIV-2 was 527, 
which represents 3.1% of the total number of AIDS cases [59]. Most of the cases (73.1%) 
were associated with heterosexual transmission and were in individuals with ages between 
35 and 54 years (60.4%). Parenteral transmission through blood transfusions or surgical 
procedures during the independence ward against Guinea-Bissau (between 1960 and 1974) 
might have been an important transmission route since sexual transmission of HIV-2 is less 




infection [61, 62]. The number of new diagnosed infections has been decreasing in the last 
ten years (from 23 new infections in 2001 to 8 in 2011) [59]. Several studies addressed HIV-2 
epidemic in Portugal over the past few years. Gomes et al found that in Lisbon and the 
Southern part of the country, between 1997 and 2002, 57% of infected patients were from 
either Guinea-Bissau or Cape Verde and the incidence was similar between genders [61]. A 
few months later, Mota-Miranda and collaborators performed a similar study in the North 
region of Portugal, with data from 1985 to 2003, and concluded that 95% of infections were 
among Portuguese individuals but in 51% of the cases a connection with West Africa was 
established [63]. Another study performed in a Lisbon hospital between 1987 and 2006 
showed a majority of infections in patients from West Africa (67.5%) and predominantly in 
women (66.9%) [64]. More recently, a large study involving several hospitals across the 
country, with data from 1985 to 2007, detected a mobility pattern of the epidemic before 
and after the year 2000. In the beginning most infected patients were Portuguese men, 
probably due to the return of Portuguese soldiers after the independence war in the late 
70’s. After 2000 a change was observed towards women of West African origin, most likely 
because of the increase in migration from West Africa to Portugal in the late 90’s [62]. 
 
Biology of HIV-2 
 
Genome and structure 
 
HIV-2 is a spherical enveloped virus with a diameter of approximately 110 nm (Figure 1.1) 
[65-67]. The envelope comprises a lipid bilayer derived from the host cell plasma membrane 
at budding, and therefore may also contain some host cell proteins from the human 
leukocyte antigen (HLA) system class I and II. Embedded in the lipid bilayer is the 
transmembrane glycoprotein (TM) bound non covalently to the outer surface glycoprotein 
(SU), this complex is arranged in trimers. Internally the viral particle is coated by the matrix 
proteins, essential to stabilize the spherical structure. Within the matrix resides the cone 
shaped capsid which contains two copies of a positive sense single stranded RNA associated 




viral maturation and early phases of replication, such as protease (PR), reverse transcriptase 
(RT) and integrase (IN) and the accessory proteins Nef, Vif, Vpr and Vpx [65-67]. 
 
 
Figure 1.1 - Electron Micrograph of HIV. The virus is more about 110 nm wide. (Adapted from 
http://www.histology.leeds.ac.uk) 
 
Each RNA molecule is about 9800 nucleotides long and is flanked by long terminal repeats 
(LTRs) at both ends (5’ and 3’). Nine genes are encoded in the compact genome, tree of 
them encode for structural or enzymatic proteins (gag, pol and env), two for regulatory 
proteins (tat and rev) and four for the mentioned accessory proteins (nef, vif, vpr and vpx) 
(Figure 1.2). The three open reading frames are used to translate all the proteins [65, 66, 68]. 
The gag encodes the polyprotein precursor Pr55Gag that is then cleaved into the proteins p26 
(capsid), p16 (matrix), p6 (nucleocapsid) and p6 (C-terminal protein) by the viral PR. The Gag 
proteins are essential for virion assembly and release. The gag and pol genes produce a 
Pr160GagPol precursor polyprotein, which is then processed by the viral PR. The pol encodes 
for tree enzymes necessary for replication: the RT (p53), the PR (p11) and the IN (p34). The 
env gene encodes for the polyprotein precursor Pr140Env, cleaved by PR in the glycoproteins 
SU (gp125) and TM (gp36). These glycoproteins are essential for viral attachment and fusion 













HIV-2’s life cycle usually begins with the binding of the virus to a specific receptor, the CD4, 
present in the cellular surface of the host cell [T-lymphocytes, monocytes, macrophages, 
dendritic cells (DC) and brain microglia] (Figure 1.3) [65, 68]. Besides CD4, other molecules 
expressed in the cell surface are essential to the interaction between virus and host cell. 
These are the chemokine receptors and work as coreceptors for HIV entry in the host cell 
[65, 68].  
After entry and uncoating of the virus in the cytoplasm, RT starts reverse transcription of the 
viral RNA into double stranded DNA, that together with the proteins IN, RT, matrix and Vpr 
form the pre-integration complex. The translocation of this complex to the nucleus is 
mediated by IN and Vpx [69]. Once in the nucleus the IN integrates the viral DNA into an 
open region of the host chromosomal genome. The proviral DNA can remain latent 
(transcriptionally silent) in the host cell or be immediately transcribed by the cellular 
machinery continuing the virus life cycle [65, 69, 70]. 
The transcription of the proviral DNA is mediated by the promoter region within the 5’ LTR 
and originates tree classes of messenger RNA (mRNA): completely spliced mRNA or early 
transcripts (Rev, Tat, Nef), incompletely spliced mRNA or late transcripts (Env, Vif, Vpr and 
Vpu/Vpx) and unspliced mRNA or late transcripts (precursor polyproteins Gag and Gag-Pol). 
All these mRNA are later incorporated in the viral particles as genomic RNA. Early transcripts 
are transported outside the nucleus like any cellular RNAm and are needed to complete the 




protein binds to the Rev responsive Element (RRE) in the RNA env region and carries the late 
transcripts to the cytoplasm to be translated [65, 70].  
The Env precursor polyproteins are translated and glycosylated before they oligomerize in 
trimers. Then the polyproteins are cleaved in SU and TM glycoproteins and transported to 
the cytoplasmic membrane. The viral RNA and proteins are directed to the cellular surface, 
where new immature viral particles are formed and released by gemmulation of the 
cytoplasmic membrane, thus acquiring the lipid envelope containing the SU/TM trimers. 
Final maturation occurs outside the cell with the cleavage of the precursor protein Gag-Pol 
by PR and posterior structural rearrangement and repositioning of the viral proteins, giving 
rise to mature and infectious viral particles [65, 70]. 
 










Molecular and structural organization 
 
As mentioned above, the envelope glycoproteins SU and TM are encoded by the env gene, 
and are responsible for the fusion between viral and host cell membranes, allowing the 
release of the viral capsid into the host cell cytoplasm. The SU and TM glycoproteins are 
associated by non covalent bounds forming trimers or spikes [71, 72]. HIV-2 spikes have 
been reported to be more prominent and stable after budding [73-75], whereas in HIV-1 
they drop immediately after budding and during maturation [71, 76]. 
Despite the high variability of SU, some structural and functional elements are conserved, 
which allowed the classification of five hypervariable regions (V1 to V5), separated by five 
more conserved regions (C1 to C5). This glycoprotein has a complex secondary structure, 
with variable regions V1 to V4 forming loops stabilized by disulphide bridges. In its native 
conformation, SU has two domains, one internal and one external [77]. The external domain 
is highly glycosylated, has most of the antigenic determinants, including neutralizing 
epitopes, and is involved in the interaction between the SU and the cellular receptor and 
coreceptors. The internal domain is hydrophobic and is essential for the SU and TM 
association. Connecting the external and internal domains there is a smaller domain 
designated bridging sheet [65, 72, 77, 78].  
The TM glycoprotein is divided in one extracellular ectodomain, one transmembrane region 
(insertion in the host cell membrane) and one intracytoplasmatic domain. The ectodomain 
has several domains common to other fusion proteins: a hydrophobic region rich in glycines 
at the N-terminal end called fusion peptide, followed by two α-helices containing leucine-
zipper motifs designated heptad repeat 1 (HR1) and 2 (HR2). The fusion peptide is essential 
for attachment to the host cell membrane. The HR motifs present repeated patterns of 
seven amino acids, being the first and fourth residues hydrophobic, mainly leucines. These 
motifs are arranged in a thermostable structure in sextuple helix, formed by trimers of HR1 




intracytoplasmatic domain mediates the binding of the envelope to the matrix protein, 
necessary for the maturation of new viral particles [65, 72, 77, 79].  
 
Interaction between the Env protein and the cell 
 
The entry of HIV into the host cell generally involves three steps mediated by the envelope 
glycoproteins: binding of the SU to the CD4 receptor, binding of the SU to the coreceptor 
and fusion of the viral envelope with the host cell membrane (Figure 1.4).  
 
 
Figure 1.4 – Model of the multi-step process of HIV entry. (Adapted from http://www.virology.uzh.ch/) 
 
The process begins with the interaction between the external domain of the SU and the CD4 
receptor. After binding to the CD4, SU suffers major conformational changes, with the 
formation of a bridging sheet and increased exposure of V1, V2, V3 and C4 regions (Figure 
1.5) [65, 72]. The folding of the bridging sheet is necessary to form the conserved part of the 
coreceptor binding site and the repositioning of the V1/V2 loop is thought to uncover this 
site [80]. All these rearrangements allow the stabilization of the SU-CD4 bond and leads to 
an approximation between the viral envelope and the host cell membrane and consequent 
interaction with the coreceptor [65, 72, 79, 81, 82]. Some HIV-2 primary isolates are known 
to infected cells independently of CD4, which implies that the coreceptor binding site in 




thought that the V3 region in some HIV-2 has a more open and exposed conformation, 
which allows it to induce conformational changes in the V1/V2 loop during fusion without 
the need to previously bind to the CD4 [82, 84, 85]. The SU-CD4 binding also induces 
changes in the TM glycoprotein: the fusion peptide becomes exposed and is inserted in the 
host cell membrane, and HR1 and HR2 fold in an antiparallel form, originating a six-helix 
bundle. The viral envelope and the host cell membrane are brought together during this 
process, leading to the formation of the fusion pore, allowing the entrance of the viral capsid 
into the cytoplasm of the target cell [65, 86, 87]. After CD4 binding, the exposure of the 
coreceptor binding site seems to be faster in HIV-2, dues leading to a more rapid fusion 
between the viral envelope and the host cell membrane, despite the lower affinity of gp125 
(HIV-2) to the CD4 receptor compared to gp120 (HIV-1) [85, 88]. This faster exposure of the 
coreceptor binding site might be due to differences in orientation of the V1/V2 loop and 
folding of the bridging sheet, as mentioned above [80].  
 
 









HIV-2 coreceptor usage and pathogenesis 
 
In vivo, the main coreceptors of HIV are the CCR5 and CXCR4. However, HIV has been shown 
to use other coreceptors [89, 90]. HIV’s tropism to cells expressing one of the coreceptors is 
related with the replication capacity of the virus in different cell lines. Viruses that infect 
preferentially macrophage cell lines, without the capacity to induce syncytia and with 
low/slow replication rates typically use the CCR5 coreceptor and are called R5 viruses. On 
the other hand, viruses that infect mainly lymphocytic cell lines, with the ability to induce 
syncytia and with high/fast replication rates, are named X4 viruses and use the CXCR4 
coreceptor. Finally, R5X4 viruses are variants with identical capacity of replicating in 
macrophage and lymphocytic cell lines and use indifferently the CCR5 and the CXCR4 
coreceptors [91-94].  
HIV-2, like HIV-1, uses mainly CCR5 and/or CXCR4 as coreceptors to enter CD4+ T 
lymphocytes. However, many HIV-2 isolates can use a wider variety of alternative 
coreceptors (like CCR1, CCR2, CCR3 and CCR8), though less efficiently than CCR5 and CXCR4 
[95]. The use of a broader range of coreceptors does not seem to be related to HIV-2’s 
pathogenicity and the relevance of using alternative coreceptors in vivo is not clarified [83, 
89, 91, 95, 96].   
In HIV-2 infection, R5 viruses are isolated from asymptomatic patients or in early stages of 
disease, and X4 variants are found in advanced AIDS [97, 98]. The emergence of X4 variants 
in HIV-2 infection seems to be related with escape from neutralizing antibodies (Nabs) 
directed against the V3 region since X4 viruses are more resistant to neutralization [97]. In 
HIV-1 infection, R5 viruses are also found in acute and asymptomatic phases. In 50% of 
infected patients, the viruses evolve to an X4 phenotype with a rapid decline of CD4+ T cells 
and progression to AIDS. However, R5 viruses can also be responsible for CD4+ T cell 
depletion and persist in advanced disease. Contrarily to HIV-2, R5X4 and X4 HIV-1 variants 
seem to be more sensitive to Nabs, which might explain why the phenotype change does not 
always occur, and when it does it’s in a stage of immune system failure [93, 99-101]. 
The major determinants for CCR5 or CXCR4 coreceptor usage by HIV-2 are located in the C-




positively charged amino acids is correlated with CXCR4 phenotype [84, 102-104]. The most 
relevant residues are in positions 18, 19 and 24 [104]. In HIV-1 the glycosylation pattern of 
V3 and V1/V2 regions also seem to influence the coreceptor phenotype [105-108]. The 
degree of glycosylation is lower in HIV-2 but the impact on coreceptor usage is still elusive 
since no clear association has been made between glycosylation of V1/V2 or V3 and 




HIV spreads through sexual contacts, contaminated blood or blood products (medical 
injections, blood transfusions and injection drug usage) and from mother to child 
(pregnancy, delivery and breast feeding) [57]. The most common route of transmission of 
HIV-2 is through heterosexual contact, as is for HIV-1, but transmission rates are 3 to 6 folder 
lower [60]. Similarly, MTCT is rare in HIV-2 with a rate below 5% compared to almost 25% in 
HIV-1 in untreated pregnant women [110-113]. A Portuguese study found a MTCT rate of 
1.5% for HIV-2 and 3.4% for HIV-1 between 1999 and 2005 and transmission was associated 
with absence of ART [114]. The reasons for the reduced transmission rates of HIV-2 are still 
not fully understood, but are probably linked to the lower plasma viremia [49, 110] and 
reduced viral shedding in the genital tract seen during HIV-2 chronic infection [115, 116]. A 
study from The Gambia found a 37-fold difference in plasma RNA levels between HIV-2 and 
HIV-1 infected untreated pregnant woman (410 versus 15,100 RNA copies/ml) [110]. On the 
other hand, a study in Ivory Coast observed that 24% of HIV-1 infected women had 
detectable RNA in vaginal secretions compared to only 5% of HIV-2 infected pears [117]. 
Detectable RNA in the semen is also lower in HIV-2 compared to HIV-1 infected men 
(2.6log10 versus 4.4log10 RNA copies/ml) [115].  
Despite being a rare event, HIV-2 MTCT has been document in both epidemiologic [111, 112, 
118-122] and molecular studies [123-125]. There is evidence that the survival rate of HIV-2 
infected is higher than their HIV-1 infected pears [126]. In fact, contrarily to HIV-1 infected 
children [127-129], disease progression and the first clinical manifestations might take many 




HIV-1 [127, 128], maternal plasma viral load does not seem to determine disease 
progression [126]. In HIV-1 infection, immaturity of the children’s immune system is thought 
to account for the fast disease progression, though time of transmission (intrauterine, 
intrapartum or postpartum) also seem to have a major influence [127, 128]. There is no 
information about immune responses in MTCT of HIV-2. 
 
Pathogenesis of HIV-2 infection 
 
The course of HIV infection can be divided into three stages: the acute phase, the chronic 
phase and AIDS [131]. The acute phase, or primary HIV infection, lasts four to eight weeks 
and is characterized by intense HIV replication and massive loss of CD4+ T cells mainly in gut 
associated lymphoid tissue (GALT). When transmission occurs through the blood 
(transfusion, IDUs or MTCT) the virus is probably removed from circulation by the 
reticuloendothelial system of the spleen, liver and lungs, with consequent infection of 
lymphoid tissue , HIV replication and dissemination within these organs [132]. Infection is 
also possible through rectal and genital mucosa (heterosexual and homosexual contacts). In 
this case DCs seem to have a central role in capturing and transporting viruses to draining 
lymph nodes and secondary lymphoid tissue where high levels of activated CD4+ T cells are 
present [131, 132]. CD4+ T cells depletion is a consequence of direct viral infection, 
activation induced cell death and host cytotoxic responses [133]. As a result of the immune 
responses directed against the infection, infected individuals experience in this phase flu like 
symptoms (acute HIV syndrome), including fever, body ache and lymphadenopathy [132]. 
Viral load, or plasma viremia, usually peaks at three to four weeks after infection but is 
eventually suppressed to a semi steady state level (viral set point) due to HIV-specific 
cytotoxic T lymphocytes (CTL) and Nabs. At this point CD4+ T cells are partially restored. The 
viral setpoint is also dependent on the individual genetic background and is an important 
determinant of disease progression in HIV-1 infection [38, 132]. In HIV-2 the viral set point is 
usually much lower compared to HIV-1 (2500 versus 70000 RNA copies/ml) [134].  
During this acute phase and early chronic phase, HIV-1 infected patients can be categorized 




(Figure 1.6). The first HIV infection marker to be detected is viral RNA that can be assessed 
by polymerase chain reaction (PCR).  The HIV-1 p24 (from gag) usually peaks 20 days after 
infection and can be detected by enzyme-linked immunosorbent assay (ELISA). Afterwards, it 
is possible to detect specific antibodies by ELISA and western blot and finally HIV-1 p31 is 
also detectable by ELISA (Figure 1.6) [135].  
 
Figure 1.6 – Fiebig clinical stages of HIV-1 infection. (Adapted from McMichael et al, Nature Reviews 
Immunology 2010 [136]) 
 
The chronic phase is asymptomatic and in untreated patients lasts about ten to 25 years in 
HIV-2 and is much faster in HIV-1 (eight to ten years) [132, 137]. At this stage, infected 
patients usually present generalized lymphadenopathy caused by persistent follicular 
hyperplasia. This period corresponds to clinical latency with low but persistent HIV 
replication in the viral reservoirs (lymphoid tissue) and constant antigen stimulation that 
drives immune activation [132]. Chronic immune activation is manifested by increased cell 
turnover, abnormal activation and differentiation of lymphocytes, increased terminal 
differentiation of B cells and increased activation-induced apoptosis of CD4+ T cells, CD8+ T 
cells and B cells, thus leading to cellular exhaustion, senescence, and low renewal potential 




might account for the slower disease progression [138-141]. Immune activation, however, 
does not seem to be directly linked to viral load in HIV-2 infection, since several studies 
reported that, despite the absence of detectable viremia, levels of immune activation were 
the same in HIV-1 and HIV-2 infected individuals when patients were matched for the same 
degree of CD4 depletion [138, 141].  
In the late phase of the infection, the immune system slowly gets exhausted by the chronic 
immune activation and depletion of CD4+ T cells and eventually collapses. This leads to 
occurrence or reactivation of opportunistic infections (like tuberculosis, candidiasis and 
pneumonia) and virus induced tumours (Epstein-Barr virus related lymphomas, Kaposi’s 
sarcoma and cervical cancer caused by Human Papillomavirus). These diseases mark the 
onset of AIDS. The Centers for Disease Control (CDC) in the USA periodically revises the list of 
clinical situations that define this stage. Another criterion that defines AIDS is the drop of 
CD4+ T cell levels below 200 cells/µl of plasma [132]. 
As mentioned above, HIV-2 infection is characterized by a slower disease progression, longer 
survival and reduced mortality rates compared to HIV-1 [57, 137, 142-147]. In fact, most HIV-
2 infected patients have normal CD4+ T cell counts, undetectable viral loads and absence of 
clinical disease [57, 134, 137, 139, 148]. Several studies showed that the probability of being 
AIDS free was near 100% in HIV-2 up to five years post seroconversion compared to 67% in 
HIV-1 infected patients [142, 149]. Mortality rates were estimated to be 2.5 to 3.5-fold lower 
per year of follow-up in HIV-2 compared to HIV-1 infection [147, 150]. Another important 
difference between the two viruses is the lower replication capacity of HIV-2 [151, 152], 
despite similar proviral loads at the same disease stage [137, 139, 153, 154]. With disease 
progression, most immunological differences between HIV-1 and HIV-2 are lost, the level of 
immune activation is the same and CD4+ T cell depletion is similar [57, 137, 138, 145-147]. 
Nonetheless, after the onset of AIDS, median time to death in HIV-2 infection was twice of 
that in HIV-1 (12.6 versus 6.3 months) and mortality rates were lower (52% versus 87% per 
year of follow-up in HIV-2 and HIV-1 infected individuals, respectively). When patients were 
adjusted for CD4+ T cell counts, mortality rates were similar in HIV-2 and HIV-1 infected 




200 cells/ml; 62% versus 73% in patients with CD4+ T counts equal or above 200 cells/ml) 
[147]. 
 
HIV-2 molecular evolution 
 
Mechanisms of viral evolution 
 
HIV and other RNA viruses shares common characteristics that make them good models to 
study evolution: high mutation rates, small genomes, large population sizes, short 
generation times and high number of offspring [155, 156]. Due to these factors HIV is one of 
the fastest evolving organisms, with an exceptionally high mutation rate of 2.4x10-5 
mutation/replication in HIV-1 [156]. It is worth mentioning that a recent study with 
Portuguese and Swedish patients found that  the rate of nucleotide substitutions in HIV-2 
gp125 and V3 is higher than in HIV-1 when patients were matched for disease stage and CD4 
dynamics (10.20x10-3 versus 6.40x10-3 substitutions/nucleotide/year in gp125 and 29.37x10-3 
versus 12.36x10-3 substitutions/nucleotide/year in V3) [157]. These mutations include 
substitutions, insertions and deletions and can appear during several steps of the replication 
cycle. Most of the point mutations are generated during reverse transcription due to the lack 
of 3’-5’ exonuclease activity of the RT enzyme [158, 159]. In addition, host enzymes may 
contribute to the mutation process, particularly the host APOBEC3 family cytidine 
deaminases that induce G-to-A hypermutations in retroviral RNA [160, 161]. When a 
mutation in a gene passes on to the offspring and coexists with the original form is called a 
polymorphism. In a population, two or more variants circulate simultaneously at a 
polymorphic site. In an HIV infected individual, the viral population consists of a pool of 
closely related variants known collectively as quasispecies [162]. 
The second major contribution to HIV genetic diversity is recombination between different 
viral variants. During one replication cycle, an estimate of 4.9x10-4 and 3.6 x10-4 
recombinations per site can happen in HIV-2 [163] and HIV-1 [164, 165], respectively. When 
a cell is infected by two different strains, the newly produced virions may comprise a 




by these virions, a recombinant proviral DNA with a mosaic genome will be generated due to 
the template switch of the RT enzyme during reverse transcription. As a consequence, large 
evolutionary and antigenic leaps may occur in just one round of replication [159, 165, 166]. 
Despite the high recombination rate seen in HIV-2, contrarily to HIV-1, CRFs are rare (for a 
review on HIV-1 CRFs see references [167] and [168]). As mentioned above, only one CRF 
has been described so far, the CRF01_AB [43, 46, 47]. The geographic restriction of the 
infection is probably a major constrain to the development of CRFs in HIV-2. Due to the 
simultaneous prevalence of both HIV-1 and HIV-2 infections in some West African countries 
and Portugal, there were concerns that an HIV-1/HIV-2 recombinant could emerge and 
produce an even more aggressive virus. In fact, recombination between the two viruses has 
been demonstrated to be possible in vitro [169]. However, in vivo, there are important 
differences between HIV-1 and HIV-2 in the signals and mechanisms of genomic RNA packing 
that impede recombination between the two viruses [170-173].  
The high replication and production rates combined with the ability to mutate and 
recombine are the bases for the high diversity of HIV; however there are other selective 
forces (natural selection) and chance events (genetic drift) that shape viral evolution [162, 
174]. Natural selection is a highly deterministic evolutionary process that promotes the 
elimination of deleterious mutations by reducing their incidence in the population (negative 
selection) and favours the fixation of beneficial mutations by increasing their frequency 
(positive selection). A mutation is deleterious if it decreases the ability of the virus to survive 
and/or reproduce in the present environment (fitness), beneficial or advantageous if it 
increases viral fitness compared to the wild type and neutral if it has no significant effect. 
Neutral mutations are not affected by natural selection. So, whenever a new mutation is 
generated it becomes either fixed or is eliminated from the population accordingly to the 
way it affects viral fitness in that given environment [162, 174, 175]. In HIV-2 and HIV-1 
infections, natural selection is a major driver of molecular evolution, due to the strong 
selective pressures imposed by the host’s immune system, mainly Nabs over the env gene 
[176-180]. 
Mutation frequencies are affected not only by natural selection but also by random genetic 




randomly through time until the mutation becomes fixed or is eliminated. These random 
events are highly affected by the population size: the smaller the population, the larger the 
effect of chance events and thus the role of genetic drift in the frequency and fate of 
mutations is more important [162, 174]. In fact, a given mutation under negative selection 
might not be entirely deleterious and become fixed in the population due to genetic drift, 
only this requires a few more generations than in the case of a neutral mutation [158, 162, 
174, 175]. 
Fixed mutations can either change the encoded amino acid, and are called nonsynonymous 
substitution, or be neutral, without change in the amino acid, and named synonymous 
substitution. Comparison between the rate of nonsynonymous substitution (dN) and the rate 
of synonymous substitutions (dS) is commonly used to characterize viral evolution and to 
investigate possible codons under positive selective pressure [162]. In this context, a dN/dS 
ratio below one implies a higher accumulation of synonymous mutations compared to 
nonsynonymous, amino acid sequences are more homogenous and there is a tendency to 
conserve the protein structure, corresponding to negative selection or purifying evolution. 
When the rate is similar or equal to one, the gene is under neutral selection. Values higher 
than one mean positive selection or adaptive evolution, and sequence variability is favoured 
and there a higher adaptation to the environment [181, 182]. In a protein coding sequence, 
conservative forces usually dominate because the functions of the proteins must be 
preserved in order for the organism to survive. However, in the context of negative 
selection, some codons might be under strong positive selection [178, 181]. 
 
Evolution of the env gene and disease progression 
 
Few studies have evaluated the HIV-2 env gene evolution in association with disease 
progression. A few years back, Sankalé and co-workers observed that fast disease 
progression was associated with higher genetic diversity (genetic variability at one time 
point) in the V3 region [183]. A transversal comparative study found that the env gene is 
under negative selection, despite the detection of strong positively selected sites across the 




infecting years and the genetic diversity of HIV-2, meaning that patients infected longer ago 
had higher genetic diversity of C2V3C3 region than virus from patients recently infected 
[184]. These authors detected a marked tendency for negative evolution in this region. In a 
longitudinal study, MacNeil and collaborators described that sequence diversity of C2V3C3 
region in HIV-2 infected patients increased over time and diversification rate was associated 
with CD4+ T cell depletion [185]. They also found evidence of negative selection in this 
region. However, they observed that diversity and divergence (genetic change from a point 
of reference) rates were significantly lower in HIV-2 infected individuals compared to HIV-1 
infected patients with high viral setpoints. In agreement, Lemey et al found that the dS was 
similar between HIV-2 infected patients and HIV-1 slow progressors (2.41x10-4 and 3.59x10-4 
substitutions/nucleotide/month, respectively), but significantly lower compared to HIV-1 
moderate progressors (5.63x10-4 substitutions/nucleotide/month). They also observed that 
the dN was in the same range in HIV-2 and HIV-1 (both moderate and slow progressors) 
infections (7.19x10-4, 7.07x10-4 and 8.68x10-4 substitutions/nucleotide/month, respectively) 
[186]. Borrego and co-workers, also in a longitudinal study, observed an increase in genetic 
diversity in C2V3C3 region through infection, but without significant association with viral 
load or clinical stage [179]. However, they showed an inverse correlation between the 
C2V3C3–specific binding antibodies [(immunoglobulin G (IgG)] and the diversity of this 
region. More recently, Skar et al. showed that the genetic evolution in gp125 and V3 (see 
above) and the rate of synonymous substitutions in gp125 are significantly higher in HIV-2 
compared to HIV-1 (13.38x10-3 versus 7.06x10-3 substitutions/nucleotide/year) [157]. The 
major difference between this study and those from MacNeil et al [185] and Lemey et al 
[186] is that Skar and collaborators [157] adjusted the samples for CD4+ T cell counts and 
disease stage, and this might account for the opposing results. Summarizing all these data, 
one concludes that the HIV-2 env gene is under negative selection, it evolves at a higher rate 
compared to HIV-1 and genetic diversity increases through infection in association with CD4+ 
T cell depletion and decrease in IgG binding antibodies [157, 177, 179, 183-186]. 
As for HIV-1 infection, several studies have compared the intrapatient evolution of the env 
gene with disease progression. During chronic infection, genetic diversity and divergence of 




201]. Recently, some authors explained these different observations by proposing a model 
where HIV evolution is a dynamic rather than a constant process [186, 196, 202]. In fact, Lee 
and collaborators developed a sequence evolution model that reflects the dynamics of 
divergence and diversity throughout infection, suggesting a direct association between the 
evolutionary rate and the changes in CD4+ T cell counts [202]. Overall, globally HIV-1 env 
gene was found to be under negative selection [203-206].  
Studies that comprised HIV-1 transmission pairs (both sexual and MTCT) found that in acute 
infection (newly infected partner or newborn) the env gene is characterized by lower 
diversity, smaller V1-V2 regions, fewer glycosylation sites and sensibility to NAbs compared 
to chronic infection (chronically infected partner or mother) [206-210]. In HIV-2 infection, 
acute infection is difficult to find, since patients are diagnosed years after seroconvertion 
[122, 211]. Therefore, there is no information on evolution of the env gene in HIV-2 acute 
infection (either adults or infants). 
 




The human immune system is capable of detecting invasion by a pathogenic intruder and to 
activate defence mechanisms in order to eliminate the infection. The innate immune 
response is the first line of defence against invading pathogens, before the development of 
an adaptive immune response [212, 213]. When encountering the immune system for the 
first time, HIV triggers innate immune receptors such as the toll-like receptor (TLR) 7, TLR8 
and TLR9, leading to the potent activation of DCs and the release of high amounts of type 1 
interferons (IFNs) and tumor necrosis factor α (TNF-α) [214-216]. IFNs and TNF- α are 
involved in shutting down viral replication in infected cells and in promoting the immune 
response by recruiting other immune cells to the sites of infection and enhancing the 
functions of macrophages, Natural Killer (NK) cells, T cells, B cells and macrophages [213, 
217]. In addition, the activation of DCs and other cells expressing TLRs induces the release of 




the receptor CCR5 [213, 217, 218]. In HIV-2 infection, as in HIV-1 infection, responsiveness to 
TLR9 is defective [219] and, despite absence of viremia, plasmacytoid DCs are decreased in 
association with CD4 depletion and immune activation [220]. Plasmacytoid DCs are major 
producers of IFN-α upon TLR9 stimulation, and therefore production of IFN-α is diminished 
in HIV-2 infection [220]. However, plasmacytoid DCs are less susceptible to infection by HIV-
2 compared to HIV-1, suggesting that other mechanisms besides direct viral infection 
determine the depletion of plasmacytoid DC during chronic HIV-2 infection [220, 221]. On 
the other hand, myeloid DCs are also less susceptible to HIV-2 and these cells’ function 
remains intact through infection [221, 222]. Likewise, and because myeloid DCs produce IL12 
upon TLR7/8 stimulation, responsiveness to this receptors as well as IL-12 production are 
preserved in HIV-2 infection [219]. However, a loss in circulating levels of myeloid DCs was 
detected in advanced disease stages in association with increase in viral load, CD4 depletion 
and immune activation [223]. Another set of cells that are better preserved during HIV-2 
infection are NK cells [224]. The cytolytic activity of these cells as well as their ability to 
release TNF-α and IFNγ during chronic HIV-2 infection is similar to that of uninfected donors. 
However, with CD4+ T cell decrease, cytolytic and chemokine-suppressive activity of NK cells 
drop to the levels seen in HIV-1 infected patients [224]. 
A robust innate immune response is mounted against HIV, but the intensity and magnitude 
of it may contribute to an early state of immune activation that promotes viral replication, 
particularly in HIV-1 infection [213, 225, 226]. Despite the better preservation of most innate 
immune responses during chronic HIV-2 infection, as mentioned above, with CD4+ T cell loss 
and increase in immune activation, most immunological differences between HIV-1 and HIV-
2 are lost and disease progression is equivalent [138, 147, 223, 224]. 
Another important component of the innate immune system that is activated upon HIV 
encounter is the complement cascade (Figure 1.7). This system is thought to participate in 
the early events of infection by recruiting DCs and macrophages to the site of infection. Also, 
it makes the bridge between the innate and adaptive immune systems by opsonisation and 
enhancement of humoral responses, and is therefore also important in the chronic phase of 




HIV replication cycle can also be blocked by several host restriction factors like Trim5-α, 
APOBEC3G and tetherin proteins [233]. Trim5-α belongs to the tripartite motif protein family 
and blocks HIV uncoating through interactions with the viral capsid [131, 137]. APOBEC3G is 
a member of the cytidine deaminases family. These proteins are packed within viral proteins 
and induce G-to-A hypermutation and degradation of the nascent proviral DNA. However, 
Vif impairs APOBEC3G’s activity [65, 131, 137]. HIV-2 seems to be more sensitive to Trim5-α 
[234] and more resistant to APOBEC3G [235] compared to HIV-1. Tetherin is a recently 
identified host restriction factor that inhibits the release of new viral particles, but HIV-2 Env 
proteins can block its activity by interacting with the tetherin cytoplasmic ectodomain 
instead of with the transmembrane domain as HIV-1 does [236-241]. Furthermore, HIV-2 Env 
sequesters tetherin from the cell surface but, unlike HIV-1, does not seem to destroy it [238].  
Other host genetic characteristics, such as HLA types, have been associated with viral 
replication and disease progression [242-244]. Of note, the HLA types considered to be 
protective in HIV-1 infection (HLA-B*27 and HLA-B*57) [242-246] showed no influence in 
HIV-2, whereas HLA-B*35, HLA-B*1503 and HLA-B*0801 were found to increase the risk of 
disease progression since individuals with these alleles had higher viral loads and lower CD4+ 
T cell counts [245, 246]. 
 
Cellular responses  
 
Most cellular responses against HIV are mediated by CD8+ T cells, also known as cytotoxic T 
lymphocytes (CTL) [132, 247]. These cells recognise viral determinants at the surface of 
infected cells through antigen presentation by HLA class I and induce direct apoptosis of 
these cells [132, 247]. CTL responses against HIV-2 are thought to be more polyfunctional 
and hence have a higher avidity and a more preserved capacity of producing TNF-α, IFNγ and 
other pro-inflammatory cytokines compared to HIV-1 infection [248, 249]. The preservation 
of CD8+ T cell functions was found to be associated with CD4 counts and decreased immune 
activation, despite the absence of detectable viral load, and is therefore thought to account 
for the slow disease progression of HIV-2 infected individuals [248]. In HIV-1 infection, CTL 




establishing and maintaining the viral set point [244, 250-252]. Usually, the virus rapidly 
escapes these early responses, forcing the T cells to become broader and target more 
conserved epitopes [250, 253, 254]. However, as disease progresses, the role of CD8+ T cells 
responses in controlling viral replication remains controversial since they have been 
positively and negatively correlated to plasma viral load [255-259].  
CD4+ T cells recognise viral determinants in the context of antigen presentation by HLA class 
II and respond by proliferating and releasing cytokines (particularly IL-2). They are essential 
in maturation of B cells (and antibody class switching) and in the activation and growth of 
CTL and macrophages. CD4+ T are the main target of HIV infection and hence are 
progressively depleted and functionally impaired through infection [132, 260]. In HIV-2 
infected individuals, the HIV-specific CD4+ T cell are thought to be more frequent, maintain 
the proliferative capacity and be more polyfunctional by sustaining the production of high 
levels of IL-2 and IFNγ compared to HIV-1 infection [249, 261-263]. HIV-1 infection is 
characterized by an early loss of CD4+ T cell responses and a decrease in proliferative 
capacity and in the ability to secrete IL-2 [264]. In chronic infection, these responses are 




Humoral immune responses are mediated by antibodies (or immunoglobulin – Ig) produced 
by B cells [267]. The Ig is composed by two heavy chains and two light chains. The amino 
terminal regions of both light and heavy chains are hypervariable between different 
antibodies and together they form the antigen binding domain. The variable regions of both 
chains along with the constant regions of the light chain and the amino terminal part of the 
constant heavy chain form the fragment antigen-binding (Fab) region. The carboxyl terminal 
regions of the heavy and light chains are constant between antibody isotypes (subclasses). 
The constant regions of the heavy chains are brought together to form the fragment 
crystallisable (Fc) region that is responsible for the effector functions of the antibody, 
namely binding to Fc receptors (FcγRs). According to their Fc portion, antibodies can be 




IgM and IgD on their surface. Upon antigen encounter, CD4+ T cells induce B cells maturation 
and isotype switch to IgG, IgA or IgE. The antibody isotype determine the effector function, 
whereas antigen specificity is determined by the antigen binding domain. The specificity and 
variability of antibodies is achieved by affinity maturation through somatic hypermutation 
and clonal selection. At the time of isotype switch, random mutations (somatic 
hypermutation) are inserted in the antigen-binding coding sequences of the Ig. The higher 
affinity mutants are selected (clonal selection) in detriment of the ones with decreased 
affinity to the antigen because they provide the cell with a proliferative advantage in 
response to that antigen [267]. 
Studies on the impact of HIV-2 infection over the B cell compartment are lacking. Since 
humoral responses are common in most HIV-2 infected patients [97, 109, 180, 268, 269], 
one could think that the B cell compartment is not affected by HIV-2. However, recently, 
Tendeiro et al described a depletion in memory B cells (unswitched and switched) in 
association with CD4+ T cell decrease, despite the absence of detectable viremia [270]. This 
imbalance, like in HIV-1 infection [271-273], was not recovered by ART [270]. No other 
studies have addressed the B cell compartment during HIV-2 infection or the relationship 
with humoral responses. Defects in global B cell function have been described in HIV-1 
infection, with a major reflexion on opportunistic infections and vaccination since humoral 
responses to other pathogens are compromised by the impairment of B cell populations 
caused by HIV-1 [274, 275]. One of the hallmarks of HIV-1 infection is hyperactivation of B 
cells in association with immune activation, with increased polyclonal B-cell activation [272], 
increased cell turnover [276, 277], increased expression of activation markers [278, 279], 
increased differentiation of B cells to plasmablasts [272, 276, 280] and decrease in memory 
B cells [271-273, 281]. Ultimately, ongoing viral replication leads to the expansion of several 
aberrant B-cell populations and B cell exhaustion [282, 283]. The consequences of B cell 
defects during HIV-1 infection in HIV-specific B cells have been the subject of recent studies 
[284, 285]. In HIV-1 infection the frequency of HIV-specific B cells was found to be quite low 
[284, 286, 287], despite the marked hypergamablobulinemia seen in these patients [272, 
279, 280, 288]. In fact, Buckner and collaborators recently reported that the cells responsible 




not HIV-specific [285]. Furthermore, these unspecific plasmablasts arise early in infection, 
which might help to explain the inadequacy of antibody response in HIV-1 infected 
individuals [285]. Nonetheless, some HIV-1 infected patients are able to produced cross-
neutralizing antibodies that do not seem to impair in quality or quantity by the B cell 
imbalances [284, 289, 290]. B cell activation and hypergamablobulinemia are also present 
during HIV-2 infection, though to a lesser extent, in association with decrease in CD4+ T cell 
counts [291-293]. Furthermore, contrarily to HIV-1 infection [294, 295], this 
hypergamablobulinemia does not seem to be polyclonal since it affects only IgGs, with no 
changes in the levels of IgA production compared to uninfected individuals [291, 293]. 
However, nothing is known about which subset of B cells is responsible for the production of 
these IgGs and whether they are HIV-2-specific. 
 
Humoral responses against Env 
 
Humoral immune responses against HIV-1 Env develop as early as eight days post-infection, 
with the first antibodies being IgM against gp41 region, followed by IgG and IgA (Figure 1.7) 
[296]. These antibodies mainly form immune complexes and generally do not control viral 
replication and are also not responsible for the initial decline in plasma viral load [296]. 
However, escape mutants have been reported to arise during this acute phase of infection 
[297, 298], implying that very low titers of Nabs are developed very early post infection 
[299]. The first autologous Nabs arise weeks after infection (13 weeks in HIV-1 clade B and 3 
to 8 weeks in HIV-1 clade C infections), target mainly the variable loops of gp120 and are 
strain specific [296, 300], but the virus rapidly evolves to escape neutralization [296, 300]. 
This leads to the development of new Nabs, and the cycle repeats itself with continuous Nab 
production and viral escape [298, 301-303]. Because of the ability of HIV-1 to escape 
neutralization, Nabs are thought to have a limited effect on the control of virus replication 
and disease course. In fact, in HIV-1 infection, only about 20% of infected individuals develop 
antibodies able to neutralize some variants from different subtypes but they take three to 
four years to develop, suggesting that antibody affinity maturation and chronic antigen 




positive correlation between the breadth of Nab response and viral diversity [176, 268, 298, 
301-303, 306, 309, 310]. The development of highly potent antibodies that neutralize the 
majority of clades is a rare event that occurs in 1% of infected patients, these individuals 
being called “elite neutralizers” [311].  
In contrast to HIV-1, most HIV-2 infected patients in the chronic phase of infection have a 
potent autologous and heterologous Nab response [97, 109, 180, 268, 269]. Weiss and co-
workers were the first to describe the presence of Nabs in HIV-2 infected patients [312]. The 
studies that followed  presented some limitations regarding the number of patients, the use 
of laboratory adapted strains and inconsistency in the neutralization assays used [84, 313]. 
Nonetheless, the work by Björling et al was the first to demonstrate that production of 
autologous Nabs was common in HIV-2 infection and to suggest an association between the 
slow disease progression of HIV-2 infected individuals and the presence of these antibodies 
[313]. More recently, Rodriguez et al found a broader Nab response in HIV-2 individuals but 
of a lower potency compared to HIV-1 (after adjusting for age and CD4+ T cell counts) and, in 
both infections, Nab titers were directly associated with viral load [268]. Kong et al found 
that Nab responses were both broad and potent, but not correlated with CD4+ T cells, viral 
load or disease outcome, and neutralization escape was rare [180]. On the other hand, 
Özkaya Sahin and co-workers reported that Nabs were both broader and more potent in 
HIV-2 infected patients and the association with viral load was only present in HIV-1 
infection [269]. de Silva et al showed that autologous and heterologous Nabs were present 
in HIV-2 infected individuals but found no association with viral load [109]. This study also 
found that higher sequence diversity and variation in putative glycosylation sites conferred 
some level of resistance to NAbs [109]. More recently, Marcelino et al in a longitudinal 
study, demonstrated that disease progression is associated with loss of breath and potency 
of NAbs in patients infected with R5 viruses and that neutralization resistance occurs in late 
stages of the disease and is associated with X4 tropism [97]. X4 tropism was also associated 
with plasma viremia. Table 1.1 summarizes the most important findings of these studies, as 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Direct comparison between all the studies remains difficult due to the use of pseudoviruses 
or clinical isolates and different neutralization assays. Most importantly, the differences in 
the populations studied may justified the discordant associations, or lack of, between Nabs 
and viral load and/or CD4+ T cell counts found in these studies. Some authors found no 
association between Nab titers and CD4+ T cell counts but the patients included in their 
studies did not represent the full spectrum of disease being in general asymptomatic and 
with high median CD4+ T cell count [180, 268]. The inclusion of patients in more advanced 
disease stages, with lower CD4+ T cell counts, was important to show for the first time, an 
association between decrease in Nab titers and CD4+ T cell depletion [97]. The same 
conclusions can be drawn regarding plasma viremia: the studies with patients presenting the 
lower median viral load (i.e. in which most patients had undetectable viral load) found no 
associations between this marker and Nab titers [180, 268], whereas those that included 
infected patients with higher plasma viremia found a positive association between viral load 
and neutralizing activity [97, 109]. Furthermore, despite being observed in two studies [97, 
109] Nab escape was shown to be really significant in the one study that enrolled patients in 
advanced disease stages [97]. This clearly points the importance of including in these type of 
studies patients with the full spectrum of disease and CD4+ T cell counts. 
In HIV-2 infection anti-Env antibodies are predominantly of IgG1 subclasses, like in HIV-1, 
although IgG3 might also be found in significant concentrations [291]. IgA antibodies are also 
thought to have an important protective role not only at the mucosal level, as in HIV-1, but 
also in the plasma [291, 293, 314, 315]. In fact, recent studies have demonstrated that 
plasma IgA in HIV-2 infection, contrarily to HIV-1, have potent neutralizing activity (Table 1.1) 
[293, 314]. During acute and chronic HIV-1 infection, antibodies against Env, as mentioned 
above, are mainly IgG1 type and higher titers of this immunoglobulin have been associated 
with better control of viral replication [316, 317]. Anti-Env IgG3 is the second most 
predominant immunoglobulin found in HIV-1 infected patients, and has in fact a greater in 
vitro neutralization capacity compared to IgG1 [316]. IgA is the predominant antibody in 
mucosal surfaces and several studies have suggested that IgA present in vaginal fluids and 




The majority of the neutralizing epitopes in HIV-2 are located in the surface of gp125 
glycoprotein. Nabs are directed against the CD4 and coreceptor binding sites 
(conformational epitopes that include selected amino acids in the C4 and V4 regions), V3 
(the linear epitope LMSGLVF and the conformational epitope comprising amino acids FHSQ 
in positions 315-318 and WCR in positions 329-331) and V4 (conformational epitope 
involving the C-terminal portion of V4) [323, 324]. Other epitopes have also been identified 
in regions V1, V2 and gp36 [314, 325-327]. Table 1.2 summarizes, in a chronological order, 
the neutralizing epitopes defined so far in HIV-2 Env. 
 
Can HIV-2-specific neutralizing antibodies neutralize HIV-1 and prevent HIV-1 acquisition? 
The early reports of modest cross-neutralization of HIV-1 by HIV-2 sera [312, 328] lead 
several authors, particularly West African groups, to investigate if HIV-2 infection provides 
cross protection against HIV-1 infection. Contrarily to initial findings [329-331], HIV-2 
infection does not seem to protect against HIV-1 acquisition and may in fact increase the risk 
of dual infection [332-336]. However, it is not clear if this higher risk is due to increased 
biological susceptibility or just risky sexual behaviour [337]. More recent studies on cross-
neutralization concluded that HIV-1 is poorly neutralized by plasmas from HIV-2 infected 
patients (Table 1.1) [268, 269]. Rodriguez et al found that neither HIV-1 nor HIV-2 were 
cross-neutralized by plasmas from HIV-2 and HIV-1 infected patients, respectively [268]. 
Özkaya-Sahin et al also found that HIV-1 was not neutralized by HIV-2 infected plamas even 
when using sera from dually infected donnors [269]. Furthermore, they found that plasmas 
from HIV-1 infected individuals neutralized HIV-1 and HIV-2 with the similar potency, and 
they atributed this phenomenon to the more neutralization-sensitive phenotype of HIV-2. 
Interestingly, however, a recent study found that disease progression of HIV-1 infected 
individuals is delayed by contemporaneous HIV-2 infection [338]. The authors found a 
significantly lower HIV-1 diversity, higher estimated time to the development of AIDS and 
higher CD4+ T cell percentage in dually infected patients than in HIV-1 infected individuals, 
and these differences were even higher in patients with HIV-2 seroconversion prior to HIV-1 
infection. However, no significant differences were found in HIV-1 divergence, 





patients and dually infected individuals [338]. Nab responses were not evaluated in these 
patients and the mechanism of protection against HIV-1 disease progression provided by 
HIV-2 was not defined. 
 
Nabs are thought to be of major importance in preventing the mother-to-child transmission 
(MTCT) of HIV-1 because mothers who transmit the virus to their infants tend to have lower 
titers of NAbs against autologous viruses than those how do not transmit [339-342]. 
Consistent with this, the homogenous population of viruses that are usually transmitted 
perinatally are thought to be neutralization escape mutants and are more resistant to 
neutralization by maternal plasma [210, 339, 340, 342-347]. However, the passive transfer of 
maternal Nabs or the development of de novo antibodies by the HIV-1 infected infant does 
not seem to influence disease outcome [129]. Regarding HIV-2, MTCT is an exceedingly rare 
event [110-113] which justifies the absence of studies on the role of maternal neutralizing 
antibodies in transmission or on the de novo development of Nabs in the infected infant. 
 
In addition to Nabs, humoral responses against HIV comprise non-neutralizing antibodies 
that bind to HIV antigens present at the surface of cells through their Fab region and recruit 
cells from the innate immune system that have an Fc receptor (FcγRs). Cells with an FcγRs 
include B cells, NK cells, DCs, neutrophils, and monocyte macrophages. The effector 
functions of these antibodies can result in one or more of the following events: antibody-
dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated viral 
inhibition (ADCVI), antibody-dependent complement-mediated inactivation (ADCMI) and 
phagocytosis (Figure 1.7) [348-358]. In HIV-2 infected patients both ADCC and ADCMI 
responses seem to be stronger compared to HIV-1, but no association has been made with 
CD4+ T cell counts or viral load [354, 359]. ADCC and ADCVI responses have been positively 
associated with CD4+ T cell counts and negatively with viral load and disease progression in 
HIV-1 infection [360-364]. A recent study evaluated the effect of complement on humoral 
responses in chronic HIV-1, HIV-2 and dual infections and found that the antiviral effect of 
ADCMI is intratype specific and more potent in HIV-2 infection than in HIV-1 infection, 




activity seen in HIV-2 infection [354]. The effector functions of antibodies might have an 
important role in controlling HIV-2 and therefore more studies addressing ADCC, ADCVI and 
ADCMI during HIV-2 infection are needed. 
 
 
Figure 1.7 – Antibody effector functions. (a) Neutralization of free virus by antibodies, (b) ADCMI, (c) 
opsonization of virus particles by antibodies and phagocytosis of virus particles via Fc- or complement-











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































HIV-2 was identified as one of the causative agents of AIDS is 1986, although its first 
transmission to humans is thought to have occurred around 1938. Presently, this virus 
affects 1 to 2 million people, the majority living in West Africa. Besides being endemic in 
several countries in West Africa, like Guinea-Bissau, Ivory Coast and Cape Verde, HIV-2 is 
only found in countries with historical and socio-culture relations with these West African 
regions, contrarily to HIV-1 responsible for the global pandemic. Apart from the confined 
geography, HIV-2 is seen as an attenuated virus compared to HIV-1, due to lower in vitro 
replication capacity and the characteristic slow disease progression and low transmission 
rate. Furthermore, human immune responses are thought to be more preserved in HIV-2 
infected individuals since most patients have strong cytotoxic responses to Env and Gag 
proteins and raise autologous and heterologous Nabs. Studying HIV-2 infection and 
understanding what is behind the better immune responses can be crucial to know how to 
control HIV-1. 
 
Several recent studies evaluated Nab responses in HIV-2 chronically infected patients and 
found them to be essential in controlling viral replication and disease progression. However, 
there is very little information on how these responses shape viral evolution in the early 
stages of the infection. Studying HIV-2 early infection might provide crucial information on 
how this virus is better controlled by the immune system compared to HIV-1. Hence, the first 
aim of these studies was to characterize the Nab response and molecular and phenotypic 
viral evolution in early infection. Because most HIV-2 infected patients are diagnosed many 
years after seroconversion, cases of MTCT represent a unique opportunity to evaluate Nab 
responses and the consequences to the virus soon after transmission. In Chapter 3, two 
children infected with HIV-2 through MTCT were followed longitudinally since birth for nine 
and twelve years. The entire env gene was amplified, cloned and sequenced in order to 
compare genetic distances, selective pressure, nucleotide evolutionary rates and putative N-
linked glycosylation sites throughout infection. Viral tropism was assessed in viruses from 
initial and subsequent sampling years in both children. Nabs responses present in the infants 
were determined against autologous and heterologous viruses using a luciferase reporter 





homology modelling using the children’s env sequences from birth and subsequent years. 
The evolution of the env gene and Nab responses were compared between the two infants 
through infection to investigate the factors behind the differences seen in the clinical 
progression of the children. Nab responses were also evaluated in parallel with viral tropism 
and structural models of C2V3C3 region to assess the importance of Nabs in tropism switch.  
 
Memory B cells are responsible for a rapid and specific antibody response on a second 
encounter with an antigen. These cells are known to be severely impaired in both HIV-1 and 
HIV-2 infections, in association with CD4+ T cell depletion. However, in contrast to HIV-1 
infected individuals, Nabs are produced by most HIV-2 chronically infected patients. What is 
the relation between Nab production and the memory B cell depletion and which B cell 
subsets are responsible for maintaining Nab production in HIV-2 infected patients? The 
answer to these questions lead to the second aim of these studies: to characterize Nab 
responses in HIV-2 chronically infected patients with several degrees of memory B cell 
disturbances and assess the correlation between these two parameters. In Chapter 4, Nab 
responses were evaluated in 37 HIV-2 chronically infected patients, which had previously 
been reported to have memory B cell imbalances. This cohort of patients included treated 
and untreated individuals, with diverse CD4+ T cell counts and varied degrees of memory B 
cell depletion. Patients’ serum was used to neutralize a panel of four heterologous R5 tropic 
HIV-2 clinical isolates in a TZM-bl reporter assay. Nab breadth and potency was then 
compared with C2V3C3 and gp36 specific binding antibodies to determine the main targets 
for neutralization in diverse stages of infection. Nab titers were also compared with the 
frequency of unswitched and switched memory B cells in the different groups of patients to 
establish the relation between Nab production and memory B cell depletion. 
 
HIV-2 resistance to antibody neutralization is a rare event that has mainly been detected in 
two X4 variants isolated early in infection from infants infected perinatally (Chapter 3) and 
four X4 strains from patients in late stage disease. Are all X4 viruses intrinsically resistant to 
Nabs? The third aim of this thesis was to characterize the neutralization phenotype of X4 




neutralization susceptibility was assessed in a new set of X4 viruses and compared with R5 
variants used as controls. X4 viruses were obtain from two vertically infected children (early 
infection) and five chronically infected adults with advanced disease (late infection). Viruses 
were neutralized with a panel of 16 plasmas from unrelated HIV-2 chronically infected 
patients in a luciferase reporter gene assay in TZM-bl cells. Amino acid sequences and 
structural models of the V3 loop (generated by homology modelling) of all strains were also 
compared to assess possible differences between R5 and X4 viruses and between X4 strains 
from early and late infections. A model of the evolution of HIV-2 V3 loop conformation 
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Background: Differently from HIV-1, HIV-2 disease progression usually takes decades 
without antiretroviral therapy and the majority of HIV-2 infected individuals survive as elite 
controllers with normal CD4+ T cell counts and low or undetectable plasma viral load. 
Neutralizing antibodies (Nabs) are thought to play a central role in HIV-2 evolution and 
pathogenesis. However, the dynamic of the Nab response and resulting HIV-2 escape during 
acute infection and their impact in HIV-2 evolution and disease progression remain largely 
unknown. Our objective was to characterize the Nab response and the molecular and 
phenotypic evolution of HIV-2 associated with Nab escape in the first years of infection in 
two children infected at birth. 
Results: CD4+ T cells decreased from about 50% to below 30% in both children in the first 
five years of infection and the infecting R5 viruses were replaced by X4 viruses within the 
same period. With antiretroviral therapy, viral load in child 1 decreased to undetectable 
levels and CD4+ T cells recovered to normal levels, which have been sustained at least until 
the age of 12. In contrast, viral load increased in child 2 and she progressed to AIDS and 
death at age 9. Beginning in the first year of life, child 1 raised high titers of neutralizing 
antibodies that neutralized primary R5 isolates more effectively than X4 isolates, both 
autologous and heterologous. Child 2 raised a weak X4-specific Nab response that decreased 
sharply as disease progressed. Rate of evolution, nucleotide and amino acid diversity, and 
positive selection, were significantly higher in the envelope of child 1 compared to child 2. 
Rates of R5-to-X4 tropism switch, of V1 and V3 sequence diversification, and of convergence 
of V3 to a β-hairpin structure were closely related with rate of escape from the neutralizing 
antibodies.  
Conclusion: Our data strongly suggests that neutralizing antibodies drive the molecular and 
phenotypic evolution of the HIV-2 envelope providing further support for a model in which 
the neutralizing antibodies play a central role in HIV-2 pathogenesis. 
 
Keywords: Vertical HIV-2 infection; evolution of the neutralizing antibody response; escape 
from neutralization; molecular evolution, tropism. 
  





Infection with human immunodeficiency virus type 2 (HIV-2) affects 1-2 million individuals 
mostly living in West Africa, India and Europe [57, 369]. Eight different HIV-2 groups named 
A through H have been reported but only viruses from groups A and B are known to cause 
human epidemics [42, 45]. Among those, viruses from group A are responsible for the vast 
majority of HIV-2 infections worldwide.  
Even though HIV-1 and HIV-2 are closely related viruses and share a high degree of similarity, 
infections by these viruses lead to very different immunological and clinical outcomes. HIV-2 
infection eventually leads to CD4 depletion, AIDS and death [145, 149, 370]. However, 
differently from HIV-1, HIV-2 disease progression usually takes decades without 
antiretroviral therapy and the majority of HIV-2 infected individuals survive as elite 
controllers with normal CD4+ T cell counts and low or undetectable plasma viral load [134, 
142, 148, 153, 291, 371-374]. Understanding of the factors involved in the effective control 
of viral replication and disease progression in HIV-2 infected individuals might prove crucial 
to devise the best strategy to prevent and treat HIV-1.  
Enhanced immune control could explain the mild outcome of most HIV-2 infections. Unlike 
HIV-1 infected patients, most HIV-2 patients in chronic stage produce potent and broad 
neutralizing antibodies [109, 180, 268, 269, 313]. Recent evidence has shown that the 
viruses isolated from HIV-2 infected patients with advanced disease are characterized by 
increased resistance to entry inhibitors, including the CCR5-antagonist maraviroc [375] and 
neutralizing antibodies [97], and by a remarkably high evolutionary rate [157, 179]. These 
results suggest that neutralizing antibodies play a central role in HIV-2 evolution and 
pathogenesis. However, in contrast to HIV-1, still nothing is known about the neutralizing 
antibody response and the molecular and phenotypic features of HIV-2 in acute/early 
infection because HIV-2 patients are usually diagnosed many years after seroconversion.  
Most neutralizing epitopes in the HIV-2 envelope glycoprotein complex are located in the 
surface gp125 glycoprotein. Neutralizing epitopes in gp125 have been identified in V1, V2, 
V3, V4 and C5 regions, and in the CD4-binding site [97, 109, 180, 323, 324, 326, 327]. These 
epitopes are well exposed in the envelope complex of CCR5-using isolates that are usually 






late stage infection in some HIV-2 patients when C2V3C3-specific neutralizing antibodies 
wane are highly resistant to antibody neutralization [97]. The V3 loop sequence, size and 
conformation of the X4 isolates are markedly different from those of R5-neutralization 
sensitive isolates supporting a direct role of this region in escape from neutralization and a 
direct role of the neutralizing antibodies in shaping the evolution of V3 in progressive HIV-2 
infection. The neutralizing domains expressed in the envelope glycoproteins in acute/early 
infection and the role of the neutralizing antibodies and neutralization escape in shaping the 
evolution of the HIV-2 envelope in this period remains to be determined.  
Perinatal transmission of HIV-2 is a rare event that in Europe has only been documented in 
Portugal [114, 122-125] and France [376]. Vertical transmission cases constitute a unique 
opportunity to study the phenotypic and molecular evolution of HIV-2 Env in acute and early 
infection as well as the role of Nabs in this process. Our objective was to characterize the 
evolution of the Nab response in two children infected with HIV-2 at birth in association with 
the molecular and phenotypic evolution of the virus. We show that broad and potent Nabs 
can be elicited very early after infection and that HIV-2 Env evolves at a very high rate in the 
first years of infection, this rate being directly associated to the potency of the Nab 
response. R5-to-X4 tropism change, increased diversity in V1 and V3, and selected changes 
in V3 conformation were associated with escape from antibody neutralization. The data fully 
supports the hypothesis that the main driver of the rapid molecular and phenotypic 
evolution of the HIV-2 envelope in the first years of infection is the selective pressure 
imposed by the neutralizing antibodies. 
 
Materials and methods 
 
Study subjects and ethics 
Two children infected by vertical transmission were studied. Blood samples were collected 
from child 1 (patient PTHDECT), 39 days after birth in 1998, in 1999, 2000, 2001, 2003, 2006 
and 2010, and from child 2 (patient PTHDESC), 27 days after birth in 1992, in 1997 and 2001. 
Clinical and immunological characteristics of the patients are shown in Table 3.1. Child 1 
started ART (stavudine+lamivudine+lopinavir/ritonavir) in November 2003. Presently, the 




child is taking lamivudine+abacavir+lopinavir/ritonavir; his viral load is undetectable and he 
is clinically and immunologically stable. Child 2 started ART with zidovudine immediately 
after birth and lamivudine was added in 2001. In 2001, viral load increased slightly and CD4+ 
T cells decreased sharply leading to the child’s death. Ethical approval was obtained from the 
Ethics Committee of Hospital Curry Cabral and written informed consent was obtained from 
the children's parents before entry into the study. 
 
HIV-2 env gene PCR amplification, cloning and sequencing  
Chromossomal DNA was extracted from infected PBMC’s using Wizard Genomic DNA 
Purification Kit (Promega) according to the manufacturer recommendations. A 2600 bp 
fragment encompassing the entire env gene was amplified by nested Polymerase Chain 
Reaction (PCR) using the Expand Long Template PCR Systemkit (Roche) and newly designed 
primers (Table S3.1). The PCR protocol consisted of denaturation at 95oC for 5 min, 35 
amplification cycles of 15 sec at 94oC, 30 sec at 59oC and 3 min at 68oC with 5 sec increments 
and a final elongation step at 68oC for 30 min. 5 µl of PCR product was used as the template 
for nested PCR. The amplification profile of the nested PCR was identical to the first PCR, 
except for annealing temperature and extension time (61oC and 2 min respectively). PCR 
amplicons were purified with a JETQUICK Gel Extraction Spin Kit (Genomed). For each 
sample, PCR products were cloned into the pcDNA3.1/V5-His-TOPO vector (Invitrogen), 
using the TOPO TA Expression Kit (Invitrogen) according to the manufacturer’s instructions. 
At least eight clones from each patient/year were sequenced using the BigDye Terminator 
V3.1 Cycle sequencing Kit (Applied Biosystems); sequencing primers are displayed in Table 
S3.1. Sequencing was performed on an ABI 3100 - Avant Genetic Analyzer (Applied 
Biosystems). 
 
























































































































































































































































































































































































































































































































































































































































































































































































































Clustal X 2.1 [377] software was used to construct alignments of HIV-2 env sequences. 
Reference HIV-2 sequences were obtained from the Los Alamos National Laboratory HIV 
sequence database [378]. Maximum likelihood phylogenetic analyses were performed using 
the best-fit model of molecular evolution estimated in PAUP by Modeltest using likelihood 
ratio tests [379]. The chosen model was GTR+I+G. Tree searches were conducted in PAUP 
using nearest-neighbour interchange (NNI) and tree-bisection plus reconnection (TBR) 
heuristic search strategies [380], and bootstrap resampling with 1000 replicates [381]. The 
genetic distances between sequences were calculated by averaging pairwise tree distances 
using all sequences obtained for each patient at each time point, as previously described 
[202]. Putative recombinants were identified using the Phi-statistic [382] available in 
SplitsTree version 4.10 [383] by performing 10 randomized reductions of putative 
recombinants. Putative recombinant sequences were removed before doing the 
evolutionary rate analyses. These were: 00PTHDECT_9, 00PTHDECT_16, 00PTHDECT_22, 
00PTHDECT_6, 00PTHDECT_24, 00PTHDECT_19, 00PTHDECT_8, 00PTHDECT_12, 
03PTHDECT_17, 03PTHDECT_33, 03PTHDECT_21, 01PTHDESC_13, 01PTHDESC_6 and 
01PTHDESC_14. 
Selective pressure on the HIV-2 Env was examined with the DATAMONKEY web-server [384], 
after removing all positions containing gaps and missing data from the dataset. All 
estimations were performed using the MG94 codon substitution model [385] crossed with 
the nucleotide substitution model GTR, previously selected with Modeltest (see above). The 
single-likelihood ancestor counting (SLAC) method was used to infer the ratio of 
nonsynonymous to synonymous nucleotide substitutions (dN/dS) averaged over all codon 
positions of the alignment. To identify individual codons under selective pressure, site-
specific dN/dS rates were estimated by the relaxed-effects likelihood (REL) method, with a 
cut-off value for the Bayes factor of 50 [386].  
The Bayesian program BEAST was used to estimate the nucleotide evolutionary rates [387]. 
The SRD06 model [388] of substitution was used and two different clock models were used, 
relaxed lognormal and strict clock. A constant parametric demographic model as well as the 





that the effective sample size for all parameters exceeded 300 and convergence was 
assessed by inspecting the traces in the program Tracer [389]. Appropriate demographic and 
molecular clock models were chosen by examining the marginal posterior distributions of 
relevant parameters.  
Potential N-linked glycosylation sites were identified using the N-Glycosite software [390] 
and the entropy at each position in protein alignment was measured with Shannon’s entropy 
[391], both available at the Los Alamos National Laboratory HIV sequence database [378].  
 
Virus isolation and tropism characterization  
Primary virus isolates were obtained from both patients using the co-cultivation method as 
described previously [124]. Viral tropism (CCR5 and/or CXCR4 usage) was determined in 
TZM-bl cells in the presence of CCR5 or CXCR4 antagonists as described previously [375]. 
Tropism was also determined genetically using the V3 loop clonal sequences and the 
algorithm described by Visseuxet al[104] which is based in the sequence, size and charge of 
the V3 loop.  
 
Neutralization assay 
The neutralizing activity present in patients serum was analyzed against autologous and 
heterologous primary virus isolates using a luciferase reporter gene assay in TZM-bl cells, as 
described previously [303, 368, 369]. Briefly, the cells [10,000 cells in 100 µl of complete 
growth medium (GM) that consists of DMEM supplemented with 10% heat-inactivated fetal 
bovine serum (FBS)], were added to each well of 96-well flat-bottom culture plates (Nunc) 
and allowed to adhere overnight. One hundred µl of each virus (corresponding to 200 
TCID50) were incubated for 1 h at 37°C with 2-fold serial dilutions of heat-inactivated 
patients sera in a total volume of 200 µl of GM containing DEAE-Dextran (20 µg/ml). The 
lowest serum dilution used in the assays was 1:80. Forty-eight hours later, plates were 
analyzed for luciferase activity on a luminometer (TECAN) using the One-Glow Luciferase 
Assay System (Promega, Madison, WI). Medium only control wells were measured as 
background, and virus-only control wells were included as 100% infection. Neutralization 
titers were expressed as the reciprocal of the plasma dilution that inhibited virus infection by 




50% (IC50). IC50 was estimated by the sigmoidal dose–response (variable slope) equation in 
Prism version 5.0 [392]. Nonspecific inhibition was assessed by testing all HIV-2 isolates 
against HIV-negative plasma and all plasma samples against HIV-1 strain SG3.1 and HIV-1 
SG3.1 pseudotyped with VSV envelope (using pSG3∆env as backbone).  
 
Structural models  
Structural models of the C2-V3-C3 domain in gp125 were produced with SWISS-MODEL 
homology modelling server in automated mode, using PDB file 2BF1 (SIV) as template [393, 
394]. Accelrys Discovery Studio 2.1 (Accelrys Inc., San Diego, USA, 2008) was used to 
produce three dimensional images of the obtained models and perform the secondary 
structure analysis of the V3 loop. 
 
Statistical analysis 
Statistical analysis was performed with GraphPad Prism 5.0 [392] with a level of significance 
of 5%. F test was used to compare best fit values of IC50 slopes obtained with CT00 and 
CT03 isolates from child 1. Non parametric Mann Whitney test was used to compare 
autologous Nab responses (mean IC50s) between child 1 and child 2. To compare 
evolutionary rates we computed the posterior probability (PP) that one rate exceeded the 
other and the probability was determined numerically by randomly sampling from the 
empirical posterior distributions [157]. Kruskal-Wallis test was used to compare mean 
Shannon’s entropies between variable Env regions of both patients. 
 
GenBank accession numbers 
Full-length envelope sequences generated in this study are available from GenBank under 












Clinical and virological progression is very fast in the first years of infection 
Child 1 infection was diagnosed with HIV-2 infection by PCR and virus isolation in the first 
month of life in 1998. To confirm the vertical transmission event and characterize the 
transmitted/founder virus population, 8 clonal full-length env gene sequences were 
obtained from samples collected in 1998, 2000 and 2003 (in total 24 env sequences) and 
from his mother (mother 1 - PTHCC20) in 2000 and 2003 (16 env gene sequences). We were 
unable to obtain 1998 samples from the mother.  
Child 2 infection was diagnosed in 1992 at day 39 after birth by PCR and virus isolation, and 
vertical transmission was confirmed by phylogenetic analysis of partial env sequences from 
the mother and the child [123, 124]. Eight new clonal full-length env sequences were 
obtained from samples collected in 1992, 1997 and 2001.  
Phylogenetic analysis showed that all sequences belonged to HIV-2 group A and that mother 
and child sequences shared a common ancestor, being more closely related to each other 
than to any other sequences, which confirms the two vertical transmission events (Figure 
3.1). The sequences showed patient-specific clustering, forming sub-clusters corresponding 
to each year of infection. The sequences from the first sample from both children segregated 
into one (child 2) or two (child 1) sub-clusters supported by high bootstrap values indicating 
that one or two virus variants were transmitted from the mothers to the children (Figure 
3.1). 
Child 1 was born with normal CD4 percentage (47%) which was sustained until age 3 without 
ART. The transmitted/founder virus was CCR5-tropic according to V3 loop sequence analysis 
of env gene clones obtained in 1998  and to phenotypic analysis of virus isolated in 2000 
(Table 3.1 and Figure 3.1). At age 5, in 2003, CD4 levels decreased to 27%, plasma viral load 
increased significantly and the virus changed to CXCR4-tropic as determined by phenotypic 
analysis. Antiretroviral therapy (ART) was initiated at that time leading to a decrease in viral 
load to undetectable levels and to an increase in CD4+ T cells to normal levels. Presently, this 
child is clinically and immunologically stable and remains asymptomatic. 
  





Figure 3.1 - - Evolutionary relationships between mother and child env sequences. A maximum likelihood 
phylogenetic tree was constructed using alignments of clonal env sequences obtained from the children in 
successive years and from their mothers with reference sequences from HIV-2 groups A, B and G. The 
bootstrap values supporting the internal branches are shown as follows: * bootstrap >70, ** bootstrap >90. 
The scale bar represents evolutionary distance in number of substitutions per site. Sequences from child 1 
(PTHDECT) are represented by red circles, with each year of sample collection in orange (1998), red (2000) and 
dark red (2003); sequences from mother 1 (PTHCC20) are represented by green circles, with each of sample 
collection in light green (2000) and dark green (2003); sequences from child 2 (PTHDESC) are represented by 
blue squares with each year of sample collection in light blue (1992), blue (1997) and dark blue (2001); 
sequence from mother 2 has been published before [32] and is represented by a pink square. The tropism of 
the viruses is indicated to the right of each cluster. Evolutionary relationships between mother and child env 






Child 2 was born with encephalopathy (CDC clinical stage C1) but with normal CD4+ T cell 
percentage (52%) and undetectable viral load [123, 124] (Table 3.1). The 
transmitted/founder virus was CCR5-tropic, as determined by our V3 loop sequence analysis, 
but induced syncytia formation in peripheral blood mononuclear cells [123, 124]. At age 5, 
CD4 percentage decreased to 25% and the virus changed to CXCR4-tropic, as determined by 
V3 loop sequence analysis. AZT therapy (1992 up to 1997) and AZT + 3TC therapy (in 2001) 
did not prevent increase in viral load and further CD4+ T cell decline and the child died of 
AIDS at age 9. 
 
Potent neutralizing antibodies are produced since the first year of infection and selects for 
Nab-resistant X4 isolates 
Nabs were detected in child 1 against both autologous virus isolates (CT00 and CT03) since 
day 27 of birth. Nab titers against the R5 isolate CT00 rose continually until age 8 (Figure 
3.2). In contrast, after an initial increase, Nab titers against the X4 isolate (CT03) dropped at 
age 2 (year 2000) and decreased continuously from age 5 onwards, the titers being 
significantly lower compared to those raised against the R5 isolate (CT00). Considering all 
time points together, Nab titers were significantly higher against the R5 isolate (CT00) 
compared to the X4 isolate (CT03) [median (range) of reciprocal log10 IC50 neutralization 
titers against CT00 and CT03 were 4.6 (3.7-5.4) and 4.1 (3.2-4.4), respectively, P = 0.0472, 
Mann-Whitney test]. The close correlation between the rates of Nab escape and R5-to-X4 
phenotypic switching suggests that phenotype transition in this infant was driven by the 
Nabs.  
Notably, child 1 also produced neutralizing antibodies that potently neutralized several 
heterologous primary HIV-2 isolates. Again, the heterologous Nabs were significantly more 
effective against R5 strains than against X4 strains [median (range) of reciprocal log10 IC50 
neutralization titers against R5 and X4 isolates were 3.5 (1.6 - 4.0) and 2.5 (1.6 - 4.0), 
respectively, P = 0.0041] (Figure 3.3).  
In child 2 we could only analyse the evolution of Nab response against the autologous X4-
isolate (SC01) from age 5 onwards. Comparing Nab response at age 5 in both patients (the 
only age-matched data point), we found that it was significantly weaker in child 2 than in 




child 1 [median (range) of reciprocal log10 IC50 neutralization titer of child 2 against SC01 was 
3.5 (3.4 - 3.6), and those of child 1 against autologous CT00 and CT03 isolates were .3 (5.0 - 
5.5) and 4.2 (4.0 - 4.4), respectively, P<0.001] (Figure 3.2). Moreover, in contrast to child 1, 
Nab titer decreased steadily with infection time as viral load increased and disease 
progressed to AIDS and death at age 9 (Figure 3.2 and Table 3.1). Considering all time points 
together, average Nab titers were lower than those of child 1 against the age-matched X4 
isolate CT03 [median (range) of reciprocal log10 IC50 neutralization titer against isolates SC01 
and CT03 were 3.3 (3.0-3.5) and 4.1 (3.2-4.4), respectively, P = 0.057] and against the R5 
isolate CT00 [median (range) of reciprocal log10 IC50 neutralization titer against isolates SC01 
and CT00 were 3.3 (3.0-3.5) and 4.6 (3.7-5.4), respectively, P = 0.0106].  
HIV-negative plasmas failed to neutralize HIV-2 strains and HIV-2 plasmas failed to neutralize 
HIV-1SG3.1 or viruses pseudotyped with VSV envelope indicating the absence of nonspecific 
inhibitory activities in these samples.  
Overall, the results obtained with child 1 demonstrate that potent neutralizing antibodies 
(autologous and heterologous) can be elicited very rapidly after HIV-2 vertical infection. 
Neutralizing antibodies are highly effective against the transmitted R5 isolates but rapidly 
select for X4 isolates that escape neutralization. In the absence of effective antiretroviral 
therapy, as was the case of child 2, increased replication of the Nab-resistant X4 isolates 











Figure 3.2 – Evolution of the autologous neutralizing antibody response in the children over the course of 
infection. The neutralizing activity present in patients serum was analyzed against their primary virus isolates 
using a luciferase reporter gene assay in TZM-bl cells; sera from child 1 from years 1998, 1999, 2000, 2001, 
2003, 2006 and 2010  were tested against autologous viruses from 2000 [CT00 (R5) - black squares] and 2003 
[CT03 (X4) – black triangles] and sera from child 2 from years 1997, 1998, 1999 and 2001 were tested against 
autologous virus from 2001 [SC01 (X4) – grey triangles]. The F test was used to compare IC50 values obtained 





























Figure 3.3 –Neutralizing antibody response against heterologous primary isolates in child 1 over the course of 
infection. A) A heat map of the reciprocal log-transformed IC50 value of each plasma sample from child 1 (left) 
against a panel of five heterologous primary virus isolates with respective tropism (top) is shown. The 
reciprocal log10 IC50 value is colour-coded. The darkest colour indicates that neutralization above 50% was still 
detected with the highest plasma dilution tested (1/5120). The lightest colour indicates that there was no 
detectable neutralization above 50% with the lowest plasma dilution tested (1/40). n.d. – not done (due to lack 
of plasma); B) Dot-plot graphic showing the mean and standard deviation of the reciprocal log10 IC50 values 
obtained against R5 and X4 isolates indicated in A. Mann-Whitney U test was used to compare the median log10 
reciprocal IC50 values. 
 
HIV-2 Env evolution in acute/early and late infection  
At birth, nucleotide diversity in child 1 was twice that of child 2 in env and five times in 
C2V3C3 region (Table 3.2). At age 5, nucleotide diversity increased 2-fold in env and C2V3C3 
in child 1 while in child 2 it only increased in C2V3C3 (2-fold) leading to an even higher 
difference in env and C3V3C3 diversity (3- and 6-fold, respectively). Interestingly, in the last 4 
years of infection in child 2, diversity increased significantly both in env (4-fold when 
compared to diversity at age 5) and C2V3C3 (11-fold) exceeding that of child 1 at age 5.  
However, in contrast to the first years of infection, most substitutions occurring in this 
period were of a synonymous nature as indicated by the sharp decrease in the ω value both 
in env and C2V3C3. 




The evolutionary rate of env was significantly higher in child 1 than in child 2 (0.0141 vs 
0.0073 substitutions/site/year, posterior probability (PP) value <5%) (Table 3.2). When 
focusing on the C2V3C3 region, the evolutionary rates were not significantly different 
(0.0142 vs 0.0105 substitutions/site/year, PP =20%). There was a trend towards positive 
selection in child 1 (non-synonymous rate: env, 0.0143 and V3, 0.0152; synonymous rate: 
env, 0.0137 and V3, 0.0124 substitutions/site/year) and purifying selection in child 2 (non-
synonymous rate: env, 0.0069 and V3, 0.0092; synonymous rate: env, 0.0082 and V3, 0.0132 
substitutions/site/year) in both env and V3. 
 













                                                                   
(95% HPD) 
env C2V3C3 env C2-V3-C3 env C2V3C3 
Child 1 
1998 0.96 1.52 0.013 (0.0061) 0.014 (0.0063) 
0.0141                               
(0.0075, 0.0211) 
0.0142                                 
(0.0082, 0.0208) 
2000 0.88 5.78 0.027 (0.0047) 0.015 (0.0074) 
2003 0.65 0.50 0.027 (0.0057) 0.031 (0.0118) 
Child 2 
1992 1.15 0.38 0.007 (0.0022) 0.003 (0.0026) 
0.0073                            
(0.0036, 0.0115) 
0.0105                                   
(0.0053, 0.0174) 
1997 0.99 2.60 0.008 (0.0025) 0.005 (0.0026) 
2001 0.66 0.62 0.035 (0.0122) 0.055 (0.0157) 
a 
Ratio of nonsynonymous to synonymous substitution rates;
 b 
Within-patient genetic distances and standard 
deviation (SD) as determined by averaging pairwise tree distances over all the sequences obtained for each 
patient at each time point; 
c 
Nucleotide substitutions per site per year (HPD, highest posterior density). 
 
We also analysed the evolution of amino acid diversity, as determined by the sum of 
Shannon’s entropy, in variable regions of gp125 which contains most of the neutralizing 
domains [109, 180, 323, 324]. At birth, amino acid diversity was higher in child 1 than in child 
2 (Table 3.3). At age 5, amino acid diversity increased significantly only in V1 and V3 in both 
patients, this being much more pronounced in child 1. In child 2, from age 5 to age 9 (death), 
amino acid diversity increased in V1 (9.3-fold), V3 (2.1-fold) and V4 (1.6-fold), though never 
reaching the level of diversity observed in child 1 at age 5. Amino acid changes observed 
after the first year in V1 and V3 are shown in Figure 3.4. In V1 there was no clear pattern of 





deletion was maintained along the full course of infection in child 2. In child 1, three 
mutations occurring at age 3 were fixed (were kept in year 5) and 4 mutations reversed back 
to the original residue suggesting that these changes affected viral fitness; in child 2, ten 
mutations were fixed over the course of infection and there were no reversions suggesting 
that the mutations did not reduce the fitness of the virus or that compensatory mutations 
occurred in other regions. Three of the fixed mutations in child 2 were located in the 
putative neutralizing epitope. In child 1 two mutations of a potentially disruptive nature 
emerged in the neutralizing epitope (N to K and T to E/G). 
 
Table 3.3 – Evolution of amino acid diversity in variable Env regions in the first five years of infection 
Patient  Variable regions 
Sum of entropy 
Fold increase 
year 1 year 5 
child 1 
V1 1.324 8.657 6.5 
V2 0 1.885 na 
V3 0.754 3.614 4.8 
V4 0.939 0.662 na 
V5 0 3.402 na 
V1-V5 3.017 18.22 6.0 
child 2 
V1 0.377 0.754 2.0 
V2 1.131 0.377 na 
V3 0.377 1.131 3.0 
V4 0 1.316 na 
V5 0.377 0 na 
V1-V5 2.262 3.578 1.6 
na- not applicable 
 
In V3, mutations occurred almost exclusively within the neutralizing epitopes, and at 
residues 18, 19 and 27 that have been associated with R5 and X4 tropism [84, 102, 104]. One 
amino acid insertion occurred in the same position in both children and involved a 
hydrophobic residue (V in child 1; I in child 2). This type of insertion has also been associated 
to R5-to-X4 tropism switch [84, 104]. 
Env adaptation to Nab pressure is usually associated with positive selection of specific amino 
acids that might be located in neutralizing domains [301]. At year 5 of infection there were 
10 positively selected sites in Env of child 1 (seven in gp125) (Table 3.4). Most sites (6 out of 




10) were located in confirmed neutralizing domains (V2, V3 and C5 in gp125 and MPER in 
gp36). In contrast, positively selected sites were absent in child 2 at year 5 of infection and 
there were only 2 selected sites in the final year of infection. These results reveal a much 
better adaptation to Nab pressure in child 1 compared to child 2.  
In all, these results show that HIV-2 env can evolve and diversify very rapidly in the first years 
of infection. The positive correlation between the rate of Env evolution, in terms of 
nucleotide divergence from the founder virus, nucleotide diversity, amino acid diversity, and 
positive selection, and the rate of Nab response and escape indicates that the neutralizing 
antibodies drive HIV-2 Env evolution in the first years of infection.   
 
Table 3.4 – Positive selective pressure on the Env glycoproteins in both children over the course of infection 
Env glycoprotein 
Codons under selective pressure (location)
1
 
Child 1 Child 2 
1998 2000 2003 1992 1997 2001 
gp125 none 5, 7 (SP) 
178 (V2), 255, 259 (C2), 320 








Codons identified as being significantly (P <0.05) under selective pressure are indicated; SP, signal peptide; V2, 
variable region 2; C2, conserved region 2; C3, conserved region 3; V3, variable region 3; V5, variable region 5; 
C5, conserved region 5; HR1, helical region 1; MPER, membrane proximal external region. 
 
Tropism and susceptibility to antibody neutralization are closely associated with V3 
structure 
In long-term HIV-2 infected individuals the envelope V3 region adopts a significantly 
different structure in Nab-resistant isolates as compared to Nab-sensitive isolates,  
supporting a direct role of V3 conformation in the different susceptibility of these viruses to 
antibody neutralization [97]. To gain some insight into the structural evolution of the V3 
region in the first years of HIV-2 infection and try to relate it to tropism and susceptibility to 
antibody neutralization, model structures of C2-V3-C3 regions from both children were 





SIV gp120 envelope glycoprotein as template. Remarkably, the V3 loop, which was 
characterized by a high content of irregular secondary structure in the first year of infection, 
converged to an similar β-hairpin structure at year five of infection in both infants and 
remained in this conformation until the last year of infection in child 2 (Figure 3.5 and Table 
S3.2). The rate of acquisition of the β-hairpin conformation fully correlated with the rate of 
R5-to-X4 tropism transition and with the rate of escape from antibody neutralization. 
 
Discussion 
There is limited knowledge on the natural history of HIV-2 infection and on the molecular 
and phenotypic evolutionary dynamics of HIV-2 because no study has investigated the full 
course of infection from the time of seroconversion. The current study is the first 
characterization of the Nab response and molecular and phenotypic evolution of HIV-2 
followed from acute infection to late stage infection. Our studies were based on two 
children infected by vertical transmission and spanned the first 12 years of infection in one 
case and the complete infection period in the other (9 years). We show that a potent Nab 
response is raised very early after infection and that the rate and pattern of molecular and 
phenotypic evolution of the HIV-2 Env are closely associated to the rate of Nab escape.  
Child 2 was born severely ill and with a low number of CD4 cells [123, 124] whereas child 1 
was born asymptomatic and with normal CD4 levels. Despite the contrasting clinical 
conditions at birth, major CD4 depletion and disease progression occurred in both children 
in the first 5 years of infection. This fast disease course is typical of HIV-1 infected children in 
the absence of antiretroviral treatment [395] but is highly unusual in HIV-2 infected 
individuals [122, 373, 396, 397]. Both patients were infected with R5 strains but transitions 
to X4 tropism occurred rapidly, being detected after only 5 years of infection. This is the first 
time that a full R5-to-X4 tropism switch is observed in HIV-2 infected patients and it was 
unexpected to find it in paediatric patients. Like in some adult HIV-2 patients with advanced 
disease [84, 97, 152], the emergence of X4 viruses in our patients was associated with high 
viral load, marked CD4 depletion and disease progression. Hence, the rapid disease course in 
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Figure 3.5 – Evolution of the structure of C2-V3-C3 envelope region. Three-dimensional structures of C2-V3-C3 
amino acid sequences from child 1 and 2 were generated by homology modelling using the three-dimensional 
structure of an unliganded SIV gp120 envelope glycoprotein as template. A) Superimposition of the structures 
of C2-V3-C3 of child 1 in 1998 (yellow), 2000 (blue) and 2003 (pale red); B) Superimposition of the structures of 
C2-V3-C3 of child 2 in 1992 (yellow), 1997 (blue) and 2001 (pale red). V3 loop and C2 and C3 stretches are 
indicated in the figures. C) Three-dimensional structures of C2-V3-C3 from child 1 (CT) in 2003 (blue) and child 2 
(SC) in1997 (red). At this time both viruses were X4 and showed resistance to Nabs. 
 
 
At birth, HIV-2 nucleotide diversity in child 1 was 2-fold higher than in child 2 both in env and 
C2V3C3. Nucleotide diversity in child 1 was also 2-fold higher than in HIV-1 infected children 
in the first weeks after birth [206, 210, 398] and in HIV-1 adult patients during 
seroconversion [399]. Envelope diversity also increased more significantly, both at the 
nucleotide and amino acid levels, in child 1 than in child 2 in the first 5 years of infection. 
Consistently, the evolutionary rate of the env gene in child 1 was almost two times higher 




substitutions/site/year) [157]. These results reveal a remarkably high rate of molecular 
evolution of the HIV-2 envelope in child 1 during the first 5 years of infection and a 
moderate rate of evolution in child 2. The evolutionary rate in child 2 was similar to that in 
HIV-1 patients who, when untreated, have a disease progression generally similar to that of 
child 2. Thus, the higher rate in child 1 is consistent with the better immune control. 
Previously, we have shown that production of gp36-specific and gp125-specific antibodies 
occurred during the first year of age in child 1 and that, at age 2, levels of binding antibodies 
to these glycoproteins were already similar to those found in HIV-2 infected patients in the 
chronic stage of disease [291]. In child 2, although gp36-specific antibodies were produced 
to near normal levels, there was a remarkably weak production of gp125-specific binding 
antibodies. Consistently, in this work we found that child 1 produced a much stronger Nab 
response than child 2. In child 1 autologous neutralizing antibodies appeared within the first 
year of infection, increased over time to levels that were similar to chronically infected 
patients [109, 180, 269], and were sustained until at least the age of 12. Moreover, child 1 
also produced a potent Nab response against several heterologous virus isolates. As for child 
2, the autologous Nab titer was significantly lower compared to child 1 at age 5 and 
decreased continuously to very low titers following the rapid decline of CD4 cells and 
progression to AIDS and death at age 9. These differences in Nab response correlate well 
with the magnitude and rate of envelope evolution in the infants which suggest a close 
association between the neutralizing antibody response and the evolution of the HIV-2 
envelope in these infants. 
Several lines of evidence further suggest that escape from Nab response is a major 
determinant of the evolution of the HIV-2 envelope in these infants, especially in child 1. 
First, complete replacement of virus quasispecies was noted in phylogenetic analysis of env 
sequences produced at the different time points which is compatible with a situation of 
ongoing viral escape from antibody neutralization [400]. Second, amino acid diversity 
increased significantly with infection time, especially in V1 and V3 which are major 
neutralizing domains in HIV-2. This is a major HIV escape mechanism as a single 
polymorphism can alter epitope sequence and/or conformation and reduce recognition 
and/or binding affinity by neutralizing antibodies [129, 176, 301, 400-402]. Third, increase in 
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dN/dS ratio and positive selection in the envelope were closely related to rate of Nab escape 
in child 1 [176, 301]. Finally, the similar gain of secondary structure in V3 in both patients 
fully correlated with the rate of escape from antibody neutralization. This has been recently 
associated to HIV-2 resistance to antibody neutralization in chronic HIV-2 infected patients 
[97].  
Nabs were significantly more potent against R5 isolates than against X4 isolates (autologous 
and heterologous) confirming the inherent resistance of X4 viruses to antibody 
neutralization [97, 368]. More importantly, increase in Nab resistance in child 1 preceded 
the emergence of X4 variant suggesting that tropism switch was driven by the neutralizing 
antibodies. Given the immunodominance of the V3 region in HIV-2 infected patients [139], 
the location of two of the three amino acid residues that are associated to R5 and X4 
tropism (positions 18 and 19) [84, 102, 104] within the first neutralizing epitope in V3 [324] 
and the major difference in V3 conformation of R5 and X4 strains [97], the close association 
between HIV-2 susceptibility to antibody neutralization and tropism is not surprising. 
The main limitations of this study are the small number of patients and the inexistence of 
viral isolates from all time points in both children. However, worldwide it has been 
impossible to find individuals acutely infected with HIV-2. Moreover, due to the low or 
absent viral load it is often impossible to isolate virus from HIV-2 infected patients. 
Therefore, we believe that even with these limitations our results are a major contribution 
to our understanding of the natural history of HIV-2 infection and of the role of the immune 
system in controlling and shaping HIV-2 evolution.  
 
Conclusions 
In conclusion, we show that a potent Nab response is elicited very early after HIV-2 infection 
and that the HIV-2 envelope evolves at a high rate in the first years of infection, this rate 
being directly correlated to the potency of the Nab response. R5-to-X4 tropism switch, 
increased nucleotide and amino acid diversity in V1 and V3, and convergence of V3 to a β-
hairpin structure were closely associated with escape from the Nab response. The data 
strongly suggests that neutralizing antibodies are the main driver of the rapid molecular and 




support to a model of HIV-2 pathogenesis in which the neutralizing antibodies play a central 
role and have clear implications for the vaccine field. 
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Table S3.1 – PCR and sequencing primers for the HIV-2 env gene.  
Primer Position Sequence 5’ – 3’ 
CR1
a
 5927 – 5946 aggaaacag(c,t)gg(a,c)gaagaga 
CR2
a
 9391 – 9369 tctacatcatccatattttg(c,t)tg 
CR3
b
 6673 – 6692 ctcat(c,t)cgtcttctgcatca 
CR4
b
 9286 – 9268 tcacaggagggcgatttct 
CRSEQ2
c
 7363 – 7345 atcccaatagtgctt(a,g)tca 
CRSEQ3
 c
 7313 – 7334 cattgcaacacatcagtcatca 
CRSEQ4
 c
 7918 - 7898 ccaattgaggaaccaagtcat 
CRSEQ5
 c
 7859 – 7879 atgtggactaactgcagagga 
CRSEQ6
 c
 8360 – 8344 gctgttgctgttgctgc 
CRSEQ7
 c
 8344 – 8360 gcagcaacagcaacagc 
CRSEQ8
 c
 8835 – 8817 gagaaaacaggcctatagc 
CRSEQ9
 c
 8817 – 8835 gctataggcctgttttctc 
CRSEQ10
 c
 7159 – 7173 agacaattgcacagg 
CRSEQ11
 c
 7424 – 7410 tggtatcattgcatc 
a
Outer PCR primer; 
b




Table S3.2 - Percentage of major secondary structure motifs present in the V3 loop of HIV-2 isolates obtained 
from child 1 and 2 
Secondary 
structure 
Child 1 (CT) Child 2 (SC) 
1998 2000 2003 1992 1997 2001 
(R5 virus) (R5 virus) (X4 virus) (R5 virus) (X4 virus) (X4 virus) 
α-helix 11.8 % 11.8 % 0.0 % 0.0 % 0.0 % 0.0 % 
β-sheet 41.2 % 41.2 % 71.4 % 5.9 % 71.4 % 71.4 % 
Turn 11.8 % 11.8 % 11.4 % 20.6 % 11.4 % 11.4 % 
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Objective: HIV-2 infection has been shown to course with significant levels of neutralizing 
antibodies (Nabs). Nevertheless, HIV-2 disease progression leads to marked memory B cell 
loss. Here, we investigated Nab responses in HIV-2 infected patients and their relationship 
with memory B cell imbalances. 
Design and methods: Thirty seven chronically infected HIV-2+ individuals were studied, 73% 
of which were antiretroviral (ART) drug naive, 76% had undetectable viral load and 59% had 
≥350 CD4+ T cells/µl. Memory B cell populations were analysed by flow cytometry. 
Neutralizing antibody titers were assessed on TZM-bl cells against a panel of four primary R5 
isolates and Env-specific binding antibodies were determined using the ELISA-HIV2 assay. 
Results: Nabs were present in all patients (median reciprocal log10 IC50 titer: 2.86; 
interquartile range: 2.64-3.10). Apart from two exceptions, all individuals neutralized at least 
two viruses (55% neutralized three or four viruses). Potency of the Nab response was 
unrelated to viral load and CD4+ T cell counts. Nab titers were positively associated with 
binding activity of C2V3C3-specific antibodies in patients with ≥350 CD4+ T cells/µl, and of 
gp36-specific antibodies in patients with more advanced disease. Remarkably, Nab titers 
correlated inversely with the frequency of unswitched and switched memory B cells in the 
untreated group of patients.  
Conclusion: The potent neutralizing antibody response elicited throughout HIV-2 infection 
occurred despite the loss of memory B cells observed with disease progression. The data 
suggests a role for long lived plasma cells in the production and perpetuation of neutralizing 
antibodies and may have important implications for the vaccine field. 
 
Keywords: HIV-2 infection, neutralizing antibodies, memory B cells




HIV-2 disease is characterized by low-to-undetectable viral load in the plasma and genital 
tract of HIV-2 infected individuals throughout infection [115, 117, 134, 403-405], a feature 
that possibly accounts for HIV-2’s lower transmissibility and pathogenic potential [110, 115]. 
Nevertheless, similarly to HIV-1, HIV-2 infection causes progressive CD4+ T cell depletion and 
AIDS, albeit at a much slower rate [138, 142, 143, 146, 406]. 
Suppression of viral replication in HIV-2 disease has been suggested to be related to well-
preserved innate and specific immune responses [57, 220-222, 224, 249, 261, 263, 285]. 
Indeed, during the chronic (asymptomatic and aviremic) phase of infection, high CD4+ T cell 
counts have been associated with the production of highly polyfunctional HIV-specific CD4+ 
and CD8+ T cells [249, 261], efficient cytolytic activity of natural killer cells [224], and 
preserved dendritic cell function and interferon-α production [220, 222, 285]. Of note, most 
HIV-2 positive individuals are able to produce and maintain high levels of broad and potent 
neutralizing antibodies, in striking contrast with their HIV-1 counterparts [109, 180, 269, 291, 
313]. This preserved Nab response seems to be related to particular features in the envelope 
glycoproteins of HIV-2 that favour antibody recognition [109, 180, 269, 291, 313, 407, 408]. 
HIV-2, like HIV-1 infection, induces polyclonal B-cell activation and hypergammaglobulinemia 
[291, 292], and disease progression occurs in direct association with increased T cell 
activation [138, 406]. Importantly, we have shown that the progression of HIV-2 disease was 
associated with a marked depletion of both switched and unswitched memory B cells not 
recovered by ART [270]. Additionally, HIV-2 disease progression leads to a significant 
decrease in the breadth and potency of Nab responses [97]. The relationship between B cell 
dysfunctions and Nab response in HIV-2 infection has yet to be determined. 
Here we evaluated Nab responses in HIV-2 infection and assessed their association with the 
previously described memory B cell disturbances [270]. All patients were found to produce 
potent and broadly neutralizing antibodies even in the presence of marked memory B cell 
depletion. Interestingly, whilst C2V3C3-specific Nabs were mainly produced before 
significant CD4+ T cell depletion occurred, gp36-specific antibodies were more characteristic 
of later disease stages. Our results suggest an important role for B cell subsets, other than 







Materials and Methods 
 
Study subjects and ethics 
The study involved 37 previously studied HIV-2 infected individuals [270]. Clinical and 
immunological data of the patients are detailed in Supplemental Digital Content 4.1. Twenty 
seven patients (73%) were untreated; 28 (76%) had undetectable viral load and 22 (59%) had 
CD4+ T cell counts above 350 cells/µl. Informed consent for blood collection and 
participation in the study was obtained from all participants. The study was approved by the 
Ethical Board of the Faculty of Medicine, University of Lisbon.  
 
Plasma viral load assessment 
HIV-2 levels of circulating virus (viremia) were quantified by RT-PCR (detection threshold: 
200 RNA copies/ml), as described [154]. 
 
Neutralization assay 
The neutralizing activity present in patients’ plasma was analysed against a panel of four 
heterologous primary R5 tropic isolates (03PTHCC6, 03PTHCC12, 03PTHCC19, 03PTHSM2) 
showing different sensitivity to IgG neutralizing antibodies [97] using a luciferase reporter 
gene assay in TZM-bl cells, as described previously [303, 368, 409]. Briefly, 10,000 cells in 
100 µl of complete growth medium (GM: DMEM supplemented with 10% heat-inactivated 
fetal bovine serum, FBS) were added to 96-well flat-bottom culture plates (Nunc) and 
allowed to adhere overnight. 100 µl of each virus (corresponding to 200 TCID50) were 
incubated for 1 h at 37°C with 2-fold serial dilutions of heat-inactivated patients’ sera in a 
total volume of 200 µl of GM containing DEAE-Dextran (20 µg/ml). The lowest plasma 
dilution used in the assays was 1:40. Forty-eight hours later, plates were analysed for 
luciferase activity on a luminometer (TECAN) using the One-Glow Luciferase Assay System 
(Promega, Madison, WI). Medium-only control wells were measured as background, and 
virus-only control wells were included as 100% infection. Nonspecific inhibition was assessed 
by testing all viruses against HIV-negative plasmas and all plasma samples from HIV-2 
Neutralizing antibody responses in HIV-2 patients with memory B cell imbalances 
77 
 
patients against HIV-1 pseudotyped with the vesicular stomatitis virus (VSV) envelope (using 
pSG∆env plasmid as a backbone). HIV-negative plasmas failed to neutralize HIV-2 strains and 
HIV-2 plasmas failed to neutralize VSV envelope pseudotyped HIV-1, indicating the absence 
of nonspecific inhibitory activities in these samples. Neutralization titers were expressed as 
the reciprocal of the plasma dilution that inhibited virus infection by 50% (IC50). IC50 was 
estimated by the sigmoidal dose–response (variable slope) equation in GraphPad Prism 
version 5.0 [392]. 
 
Env-specific binding antibodies  
Quantification of specific antibodies against HIV-2 envelope glycoproteins gp36 and gp125 
(C2V3C3 region) was performed in plasma samples from 22 patients using the ELISA-HIV2 
assay, which is a dual-antigen ELISA assay, as previously described [270, 407]. Briefly, 
microwells were independently coated (100μl/well) with the polypeptides rpC2-C3 
(containing the C2, V3 and C3 regions) and rgp36 (containing the gp36 ectodomain) and 
incubated overnight at 4°C. Microwells were blocked with 1% gelatin for 1 h and 100 μl of a 
1/100 dilution of each plasma sample was added to the wells and incubated for one hour at 
room temperature. After washing, a 1:2,000 dilution of goat anti-human immunoglobulin G 
(Fc specific) conjugated to alkaline phosphatase (Sigma-Aldrich) was added and incubated 
for one hour at room temperature. The colour was developed using p-nitrophenylphosphate 
tablets (Sigma-Aldrich) as a chromogenic substrate, and the optical density(OD) was 
measured with an automated LP 400 microplate reader (Bio-Rad) at 405 nm against a 
reference wavelength of 620 nm. The results of the assay are expressed quantitatively as 




Memory B cell populations were assessed based on the expression of CD27 and surface IgD 









Medians were estimated with interquartile range (IQR). The one-sample Kolmogorov-
Smirnov test for normality was used for continuous variables. SPSS (version 19; SPSS Inc., 
Chicago, IL, www.spss.com) was used. P values were 2-tailed and significance was defined as 
P <0.05. Non parametric Mann Whitney U test was used to compare medians of clinical and 
immunological data between treated and untreated patients, Nab titers (reciprocal log10 
IC50) against the different viruses and Nab titers between the different groups of patients. 
To study how two variables varied together, linear regression was performed and Spearman 
correlation coefficients were computed. For linear regression analysis, influential points 





Nabs are present in all HIV-2 infected patients, independently of viral load, CD4+ T cell 
counts or antiretroviral treatment 
We investigated the Nab responses in a previously described cohort of HIV-2 infected 
patients [270]. Untreated patients (n=27) had significantly higher CD4+ T cell counts 
compared to the 10 treated individuals (P=0.0043) (Supplemental Digital Content 4.1), in 
agreement with the poor response to ART that has been described in HIV-2 infected patients 
[410, 411]. All patients produced Nabs against a panel of four primary R5 isolates 
(Supplemental Digital Content 4.2). Considering all viruses, the median reciprocal log10IC50 
neutralization titer was 2.86 (interquartile ranged 2.64-3.10) (Table 4.1). There were, 
however, significant differences between the susceptibility of the four isolates to antibody 
neutralization (P<0.05) (Supplemental Digital Content 4.2). With two exceptions, all plasmas 
neutralized two or more viruses, and the majority (20/37, 55%) neutralized at least three of 
the viruses (Table 4.1). Nab titers did not differ significantly in untreated and treated 
individuals (P=0.0971), viremic and aviremic patients (P=0.5471), and patients with more or 
less than 350 CD4+ T cells/µL (P=0.6096) (Supplemental Digital Content 4.3). Considering all 
patients, there was a positive association between Nab potency and breadth (N=37, 
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Spearman rank, r=0.4055, P=0.0128) (Figure 4.1). Notably, however, this association was 
only maintained in the untreated group of patients (untreated: N=27, Spearman rank, 
r=0.4916, P=0.0092; treated: N=10, Spearman rank, r=0.3290, P=0.3487). 
 
Table 4.1 – Potency and breadth of antibody neutralization in HIV-2 infected patients 
  
Neutralizing titers  
[Median reciprocal log10IC50 
(interquartile range)] 
Breadth of neutralization 
[Number (%) of plasmas that 
neutralize the viruses]  
All plasmas/all viruses 2.86 (2.64-3.10) 37 (100) 
Neutralize 100% (4/4) viruses 3.20 (2.77-3.49) 5 (14) 
Neutralize 75% (3/4) viruses 2.82 (2.76-3.05) 15 (40.5) 
Neutralize 50% (2/4) viruses 2.86 (2.61-2.97) 15 (40.5) 








































Figure 4.1 - Association between potency and breadth of antibody neutralization. Spearman's rank 
correlation coefficient was used to assess associations between Nab titers and breadth in all patients (N=37). 








Figure 4.2 – Association between neutralizing and binding antibodies. Spearman's rank correlation coefficient 
was used to assess associations between Nab titers and levels of C2V3C3- (grey) and gp36-specific binding 
antibodies (black) in all patients (panel A), patients with CD4
+
 T cells ≥ 350 cell/µl (panel B) and patients with 
CD4
+














































Patients with CD4+ T cells/l   350 (N=13)











































Patients with CD4+ T cells/l < 350 (N=9)
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Nabs target the C2V3C3 region of gp125 in chronic infection and the gp36 ectodomain in 
late infection 
Nab titers were positively associated with the binding activity of C2V3C3-specific antibodies 
(N=22, Spearman rank, r=0.4734, P=0.026) and gp36-specific antibodies (N=22, Spearman 
rank, r=0.4758, P=0.025), indicating that they target both these regions in the HIV-2 Env 
(Figure 4.2). Notably, for the C2V3C3-specific antibodies, this association was only observed 
in patients with > 350 CD4+ T cells/µl (N=13, Spearman rank, r=0.8516, P=0.0002), whereas 
for gp36-specific antibodies it was observed only in patients with < 350 CD4+ T cells/μl (N=9, 
Spearman rank, r=0.700, P=0.043) (Figure 4.2 and Supplemental Digital Content 4.4). The 
erosion of C2V3C3-specific Nab response in later infection may be due to neutralization 
escape following sequence and/or conformational changes in V3, as previously suggested 
[291, 408]. Conversely, the presence of gp36-specific Nabs in advanced disease is consistent 
with the high conservation of this envelope region and with its overall immune dominance in 
HIV-2 infection [407]. 
 
Nab titers are inversely associated with memory B cells in untreated HIV-2 infection 
HIV-2 infected individuals showed significant memory B cell disturbances as previously 
described [270]. Both unswitched and switched memory B cells were significantly depleted 
in these patients, particularly in those with pronounced CD4+ T-cell loss, detectable viral load 
or on antiretroviral treatment [270]. Untreated patients had significantly higher levels of 
memory B cells [both unswitched (P=0.0210) and switched (P=0.0004)] compared to treated 
individuals [270] (Supplemental Digital Content 4.1).  
In the untreated group of patients (N=27), Nab titers were inversely related with both 
unswitched (Spearman rank, r=-0.4162, P=0.0308) and switched memory B cell frequencies 
(Spearman rank, r=-0.0436, P=0.0003) (Figure 4.3 and Supplemental Digital Content 4.5). 
Notably, however, these associations were maintained only in the groups of untreated 
patients with > 350 CD4+ T cells/μl and/or undetectable viral load (Supplemental Digital 
Content 4.5). Consistent with this, the strength of the correlation between Nab titers and 
frequency of memory B cell populations was higher in the untreated group of patients, 






variability in unswitched and switched memory B-cell frequencies, respectively (Figure 4.4). 
In the treated individuals, no association was found between Nab titers and memory B cell 
frequency (Supplemental Digital Content 4.5). Hence, our data suggest that, in untreated 
HIV-2 infected individuals, potent Nab responses are associated with a reduced memory B 
cell pool. 
 
Figure 4.3 - Association between neutralizing antibodies and memory B cells. Spearman's rank correlation 
























































































































Figure 4.4 – Strength of the relationship between neutralizing antibodies and memory B cells. Linear 
regression was used to assess the strength of the relationship between Nab titers and frequency of unswitched 
memory B cells in all patients (panel A), in untreated patients (panel B) and in treated patients (panel C) and 
between Nab titers and switched memory B cells in all patients (panel D), untreated patients (panel E) and 
treated patients (panel F). The results of linear regression analysis are shown with the associated correlation 
coefficients for each comparison. In panels A and D untreated patients are represented by closed circles and 




















































































































































































































To our knowledge, this is the first study addressing the relationship of Nab responses in HIV-
2 infected patients with memory B cell disturbances. We show that potent and broadly Nabs 
are produced in chronic HIV-2 patients, despite evidence of marked memory B cell loss. 
The thirty seven chronically infected HIV-2 individuals enrolled in this study showed a 
significant depletion of both unswitched and switched memory B cells, which was 
particularly marked in patients in more advanced disease stages (CD4<350 cells/µl), with 
detectable viral load or on antiretroviral treatment [270]. Interestingly, despite the marked 
memory B cell loss, all patients produced Nabs that were both broad and potent. The 
median Nab titer obtained in this study was lower than in other studies (reciprocal log10 
IC50, 2.9 vs 3.0-4.7) [109, 180, 269]. This was likely due to the inclusion in our study of a 
considerable number of patients in a more advanced disease stage, since Nab potency and 
breadth decrease as HIV-2 disease progresses [97]. Moreover, in this study we have used a 
panel of diverse primary isolates instead of the pseudoviruses and cloned viruses used in 
other studies, which are generally easier to neutralize [412].  
A positive association was found between Nab titers and breadth, meaning that patients 
with the most potent Nabs were also those with higher neutralizing breadth, which is in 
agreement with previous reports, both in HIV-1 [289, 413] and HIV-2 [97, 269] infections. 
Nab titers were also found to positively correlate with levels of C2V3C3-specific binding 
antibodies, confirming that this region contains a dominant neutralizing epitope, likely V3, 
that is expressed in most HIV-2 infected individuals [97]. Additionally, there was a direct 
association of the Nab titers with the levels of gp36-specific binding antibodies, indicating 
that the patients also produced heterologous Nabs targeting the gp36-ectodomain. 
Remarkably, Nab titers correlated with C2V3C3-specific binding antibodies only in patients 
with higher number of CD4 cells (>350 cells/µl), whereas a similar correlation with gp36-
specific binding antibodies was present only in patients in later stage disease with lower 
number of CD4 cells (<350 CD4 T cells/µl). This is consistent with the observation that 
C2V3C3-specific binding antibodies wane as disease progresses much more drastically than 
gp36-specific antibodies and is likely related to major sequence changes that occur in the V3 
neutralizing epitope during the disease course and eventually lead to R5-to-X4 tropism 
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switch and resistance to antibody neutralization [97, 291]. In contrast, the lower 
diversification of the gp36-ectodomain, likely due to a lower Nab pressure, might explain the 
more pronounced gp36-specific Nab response in late stage disease.  
Unlike HIV-1 infection, where no significant association seems to exist between Nab 
production and frequency of memory B cells [284, 290, 414], we found Nabs to correlate 
inversely with the frequency of both unswitched and switched memory B cells in the 
untreated groups of patients showing that, in HIV-2 infection, Nabs are produced regardless 
of memory B cell loss. The mechanisms underlying the correlation found between efficient 
production of neutralizing antibodies and reduced memory B cells in HIV-2 infected 
individuals require further investigation. Previous reports on several viral infections have 
shown an absence of correlation between antibody levels and circulating memory B cells, 
assuming that antibody production could have been maintained by bone marrow long-lived 
plasma cells that do not require continuous antigen exposure [415, 416]. Hence, in 
chronically infected untreated HIV-2 patients, production of neutralizing antibodies might 
also be predominantly maintained by long lived plasma cells [415, 417]. Furthermore, recent 
findings showed that plasmablasts are responsible for the elevated levels of IgGs seen in 
HIV-1 infected individuals [285]. These same cells might also be responsible for maintaining 
antibody production in HIV-2 infection, with the difference that they most likely are HIV-
specific, and produce high levels of Nabs, whereas in HIV-1 most IgGs are not HIV-specific 
[285].  
In conclusion, this study provides new insights into how Nabs are produced and maintained 
during chronic HIV-2 infection. We show that Nabs are produced throughout the course of 
disease, either against the C2V3C3 envelope region or, in advanced stage, against the gp36 
ectodomain, and that potent Nab responses occurred in the context of marked memory B 
cell loss. These data suggest a role for B cell subsets other than memory B cells, such as long-
lived plasma cells, in the production and perpetuation of neutralizing antibodies and may 
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Supplemental Digital Content 4.2 – Neutralizing antibody response against a panel of heterologous primary 
isolates. The median Nab titer (reciprocal log-transformed IC50) of each plasma sample against a panel of four 
R5 heterologous primary virus isolate is shown. The overall median values and interquartile ranges are also 
shown. Non parametric Mann Whitney U test was used to compare median Nab titers. All medians were 
statistically significant (P<0.05). 




Supplemental Digital Content 4.3 – Neutralizing antibody response in patients stratified according to 
treatment, viral load and CD4
+
 T cell counts. The median Nab titer (reciprocal log-transformed IC50) of each 
plasma sample against a panel of four R5 heterologous primary virus isolate is shown. The overall median 
values and interquartile ranges are also shown. Patients were stratified according to treatment (panel A), viral 
load (panel B) and CD4
+
 T cells category (below and above 350 cells/µl) (panel C). Non-parametric Mann 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Primary isolates of HIV-2 that use the CXCR4 co-



















Primary isolates of HIV-2 that use the CXCR4 co-receptor are 




Cheila Rochaa,b, Pedro Borregoa,b, Rita Caladoa,b, Marta Caladoa, Fernando Maltezc, José M. 





Unidade dos Retrovírus e Infecções Associadas, Centro de Patogénese Molecular, Faculdade de Farmácia de 
Lisboa, Portugal; 
b
Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Superior de Ciências da 
Saúde Egas Moniz, Monte de Caparica, Portugal; 
c
Serviço de Doenças Infecciosas, Hospital Curry Cabral, Centro 













Objective: CXCR4-tropic HIV-2 viruses isolated from patients with advanced disease were 
found to be highly resistant to IgG antibody neutralization but whether this is an intrinsic 
characteristic of these viruses remains to be determined. In this study we aimed to 
characterize the neutralization phenotype of an extended set of primary X4 isolates obtained 
from HIV-2 patients in diverse disease stages.  
Design and methods: Seven X4 variants were obtained from five chronically infected 
patients in late disease stages and two vertically infected children (early infection). 
Neutralization susceptibility of X4 isolates was determined using a luciferase reporter gene 
assay in TZM-bl cells with 16 plasmas from unrelated HIV-2 infected patients and compared 
to that of primary R5 isolates. 
Results: Early and late infection X4 viruses were significantly more resistant to Nabs than R5 
viruses (median reciprocal log10 IC50 neutralization titers: 1.60 vs 3.95, P<0.0001). Late 
infection X4 isolates were significantly more resistant to Nabs than early infection X4 
isolates. Compared to R5 isolates, X4 viruses had all of the following characteristics in V3: a 
mutation at position 18, the mutation V19K/R, an insertion at position 24 and a higher global 
net charge. Nab resistance was also associated to a significant gain in secondary structure in 
V3. 
Conclusions: Nab resistance is an intrinsic characteristic of X4 HIV-2 viruses that is likely 
determined by major sequence and/or conformational changes in the V3 region in the 
envelope glycoprotein. 
 
Keywords: HIV-2 infection, neutralizing antibodies, R5 and X4 tropism 
  





In contrast to HIV-1, most HIV-2 infected patients have normal and stable CD4+ T cell counts, 
low or undetectable viral loads and absence of clinical disease [134, 139, 148]. These 
features might be related to a more effective cellular and humoral immune response 
generated against HIV-2 [138, 140, 141, 151, 152, 268, 313, 314, 368]. With disease 
progression, CD4+ T cell depletion occurs at a similar level relative to HIV-1 and the mortality 
rate is also equivalent to HIV-1 [145, 146]. 
HIV-2 cell entry usually requires the interaction of the envelope glycoproteins with the CD4 
receptor and with co-receptors that belong to the family of chemokine receptors. Among 
those, CCR5 and CXCR4 are the most important HIV-2 co-receptors [83, 84, 95, 96, 98, 418] 
but some primary isolates from asymptomatic patients may infect peripheral blood 
mononuclear cells (PBMCs) independently of these co-receptors [419]. Other isolates may 
even infect CD4-negative cells using CCR5 or CXCR4 as main receptors [83]. Most chronically 
infected HIV-2 patients (usually asymptomatic and aviremic) harbour CCR5-using (R5) strains 
[89, 420]. CXCR4-tropic (X4) HIV-2 isolates have only been found in patients with advanced 
disease and low CD4+ T cell counts and are strongly associated with faster disease 
progression compared to R5 isolates [84, 89, 97, 420]. The V3 loop in the gp125 envelope 
glycoprotein is the main determinant of HIV-2 co-receptor usage and tropism and its charge, 
size and structural conformation seem to directly influence interaction with CCR5 or CXCR4 
[84, 97, 102, 368, 421].  
In contrast to HIV-1, most HIV-2 patients in chronic stage of infection have a potent and 
broad Nab response against R5 isolates [84, 97, 109, 180, 268, 269, 313]. Nonetheless, the 
potency of the Nab response against R5 isolates decreases with CD4+ T cell depletion and a 
minority of R5 isolates and all X4 viruses isolated from patients with advanced disease are 
highly resistant to plasma autologous and heterologous IgG neutralization [97]. Interestingly, 
mice immunized with envelope antigens from the reference R5 isolate (HIV-2ALI) produced 
antibodies that potently neutralized heterologous R5 primary isolates but not X4 isolates 
[368]. These results suggest that the susceptibility of HIV-2 to antibody neutralization is 
associated with co-receptor usage and that resistance to antibody neutralization is an 




In the present study we aimed to characterize the neutralization phenotype of an extended 
set of primary X4 isolates obtained from HIV-2 patients in diverse disease stages. We provide 
definitive evidence that Nab resistance is an intrinsic characteristic of X4 HIV-2 viruses that is 





Viruses, study subjects and ethics 
Five X4 variants were obtained from five adult chronically infected patients in late disease 
stage (median CD4+ T cells/µl=78; interquartile range=31.5-221) and two additional X4 
variants were obtained from two vertically infected children at age 5 (early infection) 
(median CD4+ T cells/µl=319.5; interquartile range=44-595). Three primary R5 isolates were 
obtained from chronically infected patients with median CD4+ T cells/µl=275; interquartile 
range=66-615). Sixteen plasmas from unrelated HIV-2 infected patients (median CD4+ T 
cells/µl=333; interquartile range=194.5-480) were used to neutralize the X4 and R5 viruses. 
Informed consent for blood collection and participation in the study was obtained from all 
participants or their mothers (in the case of the two vertically infected children). The study 
was approved by the Ethical Board of the Hospital de Curry Cabral, Lisbon.  
 
Neutralization assay 
Neutralization assays were performed using a luciferase reporter gene assay in TZM-bl cells 
as described previously [290, 368, 409]. Briefly, the cells [10,000 cells in 100 µl of complete 
growth medium (GM) that consists of DMEM supplemented with 10% heat-inactivated fetal 
bovine serum (FBS)], were added to each well of 96-well flat-bottom culture plates (Nunc) 
and allowed to adhere overnight. 100 µl of each virus (corresponding to 200 TCID50) were 
incubated for 1 h at 37°C with 2-fold serial dilutions of heat-inactivated patients sera in a 
total volume of 200 µl of GM containing DEAE-Dextran (20 µg/ml). The lowest serum dilution 
used in the assays was 1:40. Forty-eight hours later, plates were analysed for luciferase 
activity on a luminometer (TECAN) using the One-Glow Luciferase Assay System (Promega, 




Madison, WI). Medium-only control wells were measured as background, and virus-only 
control wells were included as 100% infection. Nonspecific inhibition was assessed by testing 
all viruses against HIV-negative plasmas and all plasma samples from HIV-2 patients against 
HIV-1 pseudotyped with the vesicular stomatitis virus (VSV) envelope (using pSG∆env 
plasmid as a backbone). HIV-negative plasmas failed to neutralize HIV-2 strains and HIV-2 
plasmas failed to neutralize VSV envelope pseudotyped HIV-1, indicating the absence of 
nonspecific inhibitory activities in these samples. Neutralization titers were expressed as the 
reciprocal of the plasma dilution that inhibited virus infection by 50% (IC50). IC50 was 




Statistical analysis was performed with GraphPad Prism 5.0 [392] with a level of significance 
of 5%. Non parametric Mann Whitney U test was used to compare medians of reciprocal 
log10 IC50 neutralization titers between X4 viruses, X4 viruses from late infection, X4 viruses 




X4 viruses from late and early infection are more resistant to antibody neutralization than 
R5 viruses 
Nab sensitivity of a panel of seven X4 viruses, including five isolates from patients in late 
disease stage and two variants from early infant infection, was analysed in parallel with 
three R5 variants. CD4+ T cell counts were not significantly different between patients 
providing the X4 and R5 strains (median, 78 vs 275 CD4+ T cells/μl, P=0.2667). All patients 
infected with R5 variants and four out of five infected with X4 strains had undetectable viral 
loads (< 200 RNA copies/ml). One individual chronically infected with an X4 virus and the 
two children also infected with X4 variants had viral loads of 4792, 20968 and 1250 RNA 






Figure 5.1 – Antibody neutralization of the X4 isolates. Panel A – A heat map of the median reciprocal log10 
IC50 neutralizing titer of each heterologous plasma sample (right) against the seven X4 isolates and the three 
R5 isolates (bottom) is shown. The reciprocal log10 IC50 value is colour-coded. The darkest colour represents 
the highest neutralizing titer; the lightest colour indicates that there was no detectable neutralization above 
50% with the lowest plasma dilution tested (1/40). Panel B – Dot-plot graphic showing the median reciprocal 
log10 IC50 neutralizing titers and interquartile range of 16 heterologous plasma samples against X4 isolates 
from early and late stage disease and R5 isolates as controls. Mann-Whitney U test was used to compare the 




X4 late X4 early R5 
Viruses 
<1.6 2.5 2.8 3.0 2.8 3.2 3.3 3.1 3.3 6.5 HCC1 
<1.6 <1.6 <1.6 2.6 2.3 3.4 3.6 <1.6 4.5 6.1 HCC2 
<1.6 <1.6 <1.6 <1.6 <1.6 2.8 2.4 <1.6 2.7 5.0 HCC3 
<1.6 <1.6 <1.6 2.1 <1.6 3.2 3.3 2.1 4.2 6.1 HCC4 
<1.6 <1.6 <1.6 <1.6 2.2 3.1 3.4 3.0 3.9 5.3 HCC5 
1.8 <1.6 1.7 <1.6 2.6 3.4 3.3 3.1 3.2 6.1 HCC7 
<1.6 <1.6 <1.6 <1.6 <1.6 3.3 3.4 3.0 4.5 5.0 HCC8 
<1.6 <1.6 <1.6 <1.6 <1.6 2.5 3.3 2.2 3.3 4.1 HCC9 
<1.6 <1.6 <1.6 <1.6 2.7 2.8 2.9 2.3 4.1 4.4 HCC13 
<1.6 <1.6 <1.6 <1.6 3.7 3.3 3.4 2.0 3.9 5.1 HCC14 
<1.6 <1.6 <1.6 <1.6 3.5 3.1 2.8 2.5 4.0 4.3 HCC15 
<1.6 <1.6 <1.6 <1.6 1.7 2.3 2.8 2.0 3.0 4.9 HCC16 
<1.6 <1.6 <1.6 <1.6 <1.6 2.7 2.9 2.5 3.9 4.8 HCC17 
<1.6 <1.6 <1.6 <1.6 <1.6 2.3 2.4 2.2 4.1 5.7 HCC18 
<1.6 1.9 1.7 2.3 3.4 3.2 2.9 2.6 4.3 5.4 HCC19 

























































































































































Figure 5.1 (continued) 
 
All viruses were neutralized by at least one plasma sample (Figure 5.1A). R5 isolates and 
early infection X4 variants were neutralized by all plasma samples whereas X4 strains from 
late disease stages were only neutralized by 50% (8/16) of the plasma samples. Neutralizing 
antibody titers were significantly higher for R5 isolates compared to X4 viruses (median 
reciprocal log10 IC50: 3.95 versus 1.60, P<0.0001). Within the X4 isolates, median Nab titers 
were significantly higher for early infection isolates compared to late infection isolates 
(median reciprocal log10 IC50: 3.10 versus 1.60, P<0.0001). Nonetheless, early infection X4 
viruses were still significantly more difficult to neutralize than R5 viruses (median reciprocal 
log10 IC50: 3.10 versus. 3.95, P=0.0101) (Figure 5.1B). These results show that X4 HIV-2 
isolates are intrinsically more resistant to antibody neutralization than R5 isolates and 
suggest that this phenotypic feature in X4 isolates is acquired with infection time.  
 
Features of the V3 neutralizing domain in R5 and X4 isolates 
Tropism switch and susceptibility to antibody neutralization in HIV-2 has been associated 
with particular changes in the envelope V3 region [84, 104, 291]. We therefore compared 




had all of the following characteristics in V3: a mutation at position 18, the mutation V19K/R, 
an insertion in position 24 and a global net charge ≥ 7 (Figure 5.2). Moreover, the V3 region 
of early infection X4 viruses had a lower mean global net charge compared to late infection 
X4 isolates (+8 and +9, respectively).  
 
 
Figure 5.2 – Alignment of the amino acid sequences of the V3 loop of the X4 and R5 isolates. Dots in the 
alignments indicate sequence identity to the first R5 isolate sequence (03PTHCC6); dashes indicate deletions; 
amino acids in grey boxes are involved in tropism change [104]; viral tropism, as determined phenotypically 
[422] and genotypically based on V3 loop sequence patterns, and disease stage are indicated at the right of the 




To investigate if resistance to antibody neutralization is an intrinsic characteristic of primary 
isolates of HIV-2 that use the CXCR4 co-receptor, we characterized the neutralization 
phenotype of a panel of X4 isolates obtained from recently infected patients and from 
patients with long-term chronic infection against 16 heterologous plasmas from unrelated 
HIV-2 infected patients. We found that X4 isolates from early and late infection are 
significantly more resistant to antibody neutralization compared to the R5 viruses. These 
results provide strong and definitive evidence that Nab resistance is an intrinsic 
characteristic of primary isolates of HIV-2 that use the CXCR4 co-receptor.  
03PTHCC6   : CRRPGNKTVVPITLMSGLVFHSQP---INRRPKQAW 
03PTHCC12  : ........................---......... 
03PTHSM2   : ........................---..T...... 
03PTHCC20  : ..............G..RR..G.RFHS......... 
03PTHSM9   : ..............G..QR..FR.--R.....M... 
10PTHSMAUC : .................FK.....--V......... 
03PTHCC10  : .................YK...R.--V..Q..M... 
04PTHSM10  : ..............Q..KR..FR.--V..Q...... 
03PTHDECT  : .................YR....A--V..T...... 





X4 late stage 
(+7/+8/+9/+11) 
X4 early stage 
(+7/+9) 




The V3 region in the HIV-2 gp125 envelope glycoprotein is a major neutralizing domain [180, 
323, 324] and also contains the most important molecular determinants of CXCR4 and CCR5 
usage [84, 97, 102, 368, 421]. To look for sequence correlates of Nab resistance we 
compared the V3 sequences of Nab-resistant X4 isolates with those of Nab-sensitive R5 
isolates. Compared to the R5 isolates, the V3 region of all X4 strains had a mutation at 
position 18, the mutation V19K/R, an insertion in position 24 and a global net charge ≥7. 
These V3 features have been associated to CXCR4 usage [84, 97, 102, 368, 421] thus 
establishing a close link between CXCR4 usage and resistance to antibody neutralization and, 
more generally, between HIV-2 tropism and susceptibility to antibody neutralization.  
Resistance to neutralizing antibodies can be developed soon after HIV-2 infection has shown 
in the X4 isolates obtained at year 5 of infection from the two infants.  However, Nab 
resistance was significantly more pronounced in isolates from chronically infected patients 
suggesting that acquisition of Nab resistance it is a stepwise process that occurs over the 
course of infection and might be driven by the constant selective pressure exerted by the 
Nabs on the envelope glycoproteins. A similar stepwise process has been recently proposed 
for acquisition of maraviroc resistance in HIV-2 infected patients undergoing maraviroc 
therapy [422].  
The V3 loop in the gp125 envelope glycoprotein of HIV-2 seems to acquire a higher level of 
secondary structure with disease progression. Indeed, the V3 loop of most R5 strains from 
chronically infected adult patients (asymptomatic and aviremic despite long-term infection) 
is characterized by the absence of a regular secondary structure whereas the V3 loop of X4 
viruses found in late infection in adult patients either acquires a β-α-β conformation or a 
helix-loop-helix conformation (Figure 5.3) [97]. Likewise, the V3 loop of R5 strains from 
recently infected children also shows absence of regular secondary structure, and on the 
other hand, X4 viruses in early infection present a β-hairpin conformation (Figure 5.3) (Rocha 
et al, submitted). These different conformations of the V3 region are a consequence of the 
evolving changes at the amino acid level and might be responsible for the marked 
differences in Nab sensitivity of HIV-2 isolates over the course of infection. We propose a 
model were, throughout infection, the pressure exerted by Nabs over the V3 loop forces the 




changes over time also favour tropism switch and are closely associated with CD4+ T cell 
decline (Figure 5.3). 
In conclusion, our results show that Nab resistance is an intrinsic feature of CXCR4- tropic 
HIV-2 isolates that is acquired over the course of infection in close association with sequence 
and conformational changes in the envelope V3 loop that also favour R5-to-X4 switch. 
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Figure 5.3 –Model of the evolution of HIV-2 V3 loop conformation with infection time and disease 
progression. The diagram shows a model of the evolution of the secondary structure of the V3 loop of R5 and 
X4 isolates with disease progression. The drawings were based on homology modelling data that has been 
published previously [97] or is submitted for publication (Rocha et al., submitted). The different secondary 
structures of V3 region are represented in grey, blue and red  and the neighbouring C2 and C3 regions are 
represented in black. The V3 region evolves from not having a regular secondary structure R5 
founder/early/chronic), to extended β-strands (R5 chronic), to a β-hairpin conformation (X4 early) or a β-α-β or 
helix-loop-helix conformation (X4 late). The yellow triangle represents increase in infection time; the blue 
triangle represents decrease in CD4
+
 T cell counts through infection; the red triangle represents increase in 






































Many aspects of HIV-2 infection remain largely unknown, which poses as an obstacle for 
vaccine design, treatment and ultimately patient care. When trying to make a parallel 
between HIV-1 and HIV-2, one faces the problem of two completely different disease 
courses, incomparable natural history and unmatchable immune responses, despite both 
viruses belonging to the same genus. Furthermore, HIV-2 can be seen as an attenuated form 
of HIV infection and the differences in virus-host interactions are most likely responsible for 
the distinct outcomes. Studying and understanding these interactions can ultimately be used 
to infer the type of immune responses that a vaccine against HIV-1 needs to elicit in order to 
be efficient. One of the major contrasts between these two infections is the production of 
broad and potent Nabs by HIV-2 infected patients. These antibodies, in parallel with other 
immune responses, are thought to have a crucial role in controlling viral replication and 
disease progression in the chronic phase of infection. Yet, until very recently, information 
was lacking on the origin of the NAbs in HIV-2 patients, on the characteristics of the Nab 
response in acute and early HIV-2 infection and on the evolution of the virus to deal with the 
neutralizing antibodies. Hence, one objective of this work was to characterize the Nab 
response and viral evolution in early HIV-2 infection. It was found (Chapter 3) that Nabs can 
be detected very early in infection and have a major impact in viral evolution. In the setting 
of a broad and potent Nab response (child1), viral diversity and evolutionary rate were 
extremely high (similar to HIV-2 chronically infected patients undergoing treatment) [157], 
whereas in the presence of a weaker Nab response (child2) these evolution markers were 
similar to HIV-1 in newly infected children and adults [206, 210, 398, 399]. Escape from 
neutralization was detected at year five of infection, has shown by the increasing resistance 
to Nabs seen in both infants. Furthermore, and consistent with the escape, there was a 
complete replacement of virus quasispecies and an increase in diversity, dN/dS rate and 
positively selected sites throughout infection. The increased resistance to neutralization was 
associated with the R5-to-X4 tropism switch, providing further evidence for the previously 
described association between Nab escape and X4 tropism [97]. In this study, however, the 
emergence of X4 tropic viruses was abnormally fast, since these strains are usually detected 
in chronically infected patients in more advanced disease stages [97]. This difference 




and acute infection occurred when they were newborn. Hence, transposition of these results 
to adult early HIV-2 infection is limited and must be made with care. Another interesting 
finding in this study was that R5-to-X4 tropism switch was associated with amino acid 
mutations in V3 region that had a major impact in the secondary structure of this region. The 
V3 loop of R5 viruses from both children were characterized by the absence of regular 
secondary structure, whereas the X4 strains showed a β-hairpin conformation. These 
findings suggest that the gain of structure in the V3 makes this region unrecognisable to 
Nabs leading to escape. Besides the changes in structure, V3 region increases in size due to 
the insertion of an amino acid in position 24, which might also influence Nab recognition. 
One important issue is the influence of antiretroviral treatment in disease outcome of these 
infants, despite the fact that response to antirretroviral treatment is weak in HIV-2 infected 
patients [411, 423-426]. Child 2 initiated treatment immediately after birth but there were 
not many therapeutic options at that time (1992). Child 1’s antirretroviral treatment started 
more than 10 years later, when an arsenal of drugs were available, and these most likely 
controlled viral load and probably also played a role in increasing diversity and evolution 
rate. More studies with HIV-2 infected patients in early stages of the disease are needed, to 
confirm our findings and address other unanswered questions. For instance, what is the role 
of maternal antibodies in HIV-2 MTCT? Are Nabs produced by recently infected adults more 
broad and/or potent than in children and is the viral evolutionary rate in these adults, with a 
capable immune system, similar to that of child1? Studying early HIV-2 infection seems a 
very difficult task, for patients are only diagnosed several years after seroconversion and 
vertical transmission is a rare event [114, 122-125, 376]. To overcome this obstacle, 
incidence cohorts should be established in countries with high prevalence of HIV-2, such as 
Guinea-Bissau and Cape Verde [33, 48, 51, 427], in order to increase the possibility of finding 
recently infected individuals or even seroconversion.  
 
Memory B cell populations were found to be depleted in HIV-1 and HIV-2 infections, in 
association with T cell activation, an imbalance not recovered by ART [270, 271, 280, 282]. 
However, in contrast to HIV-1, HIV-2 patients are able to produce high levels of broadly 
neutralizing antibodies. Understanding, which subset of B cells is responsible for inducing 




and maintaining the high levels of broad and potent Nabs found in HIV-2 infection might be 
important for the development of a vaccine against both HIV-2 and HIV-1. Hence, the second 
objective of this work was to investigate the Nab response in HIV-2 patients with different 
levels of B cell depletion and the relationship between the Nab response and the different 
subsets of memory B cells. In Chapter 4, it was found that HIV-2 infected individuals 
produced broad and potent Nabs despite memory B cell disturbances. Nabs were negatively 
correlated with frequency of both unswitched (CD19+CD27+IgD+) and switched 
(CD19+CD27+IgD-) memory B cells in untreated patients which suggests that memory B cell 
depletion somehow favours Nab production and implies that Nab production is maintained 
by other B cell subsets. In HIV-1 infected individuals, there is no association between Nab 
production and any B cell subset [284, 289, 290]. The lack of association between Nabs and 
memory B cells in HIV-1 is not surprising since Nabs are rare and take many years to develop 
[306, 307], and hence they are produced in a setting of major B cells imbalances. In HIV-1 
infection the levels of terminally differentiated B cells (plasmablasts and plasma cells) are 
increased very early after transmission leading to hypergamablobulinemia [272, 279, 428-
430]. Importantly, the majority of IgGs present in HIV-1 infected patients is not HIV-specific 
[285, 431]. Since hypergamablobulinemia is also present in HIV-2 infection and memory B 
cells are depleted [270, 291, 292], it is reasonable to think that plasmablasts and plasma 
cells might also be increased in HIV-2 infected individuals. In contrast to HIV-1, however, 
these antibody producing cells are most likely responsible for the production and 
maintenance of elevated levels of Nabs in HIV-2 infection. Further studies are needed to 
evaluate if plasmablasts and/or plasma cells are indeed increased in HIV-2 infection and to 
determine which B cell population is responsible for HIV-2-specific antibody production 
(binding and neutralizing). With this information one would perceive which subset of B cells 
is important to stimulate in vaccination in order to continuously produce antibodies capable 
of neutralizing HIV-1 and HIV-2. It is also crucial to know the epitopes targeted by these 
Nabs. Hence, another important finding in our study was the association between Nabs and 
C2V3C3-specific antibodies in patients with high CD4+ T cell counts and with gp36- specific 
binding antibodies in later disease stages (<350 CD4 T cells/µl). The V3 region of HIV-2 is 




described in gp36 [314, 325, 327]. However, this is the first study to describe a change in 
Nab recognition from C2V3C3 region to gp36 with disease progression. The results show that 
most Nabs are directed against a dominant neutralizing epitope in C2V3C3 (probably in V3) 
but as disease progresses, changes in this region most likely make it unrecognisable to Nabs. 
These changes also lead to R5-to-X4 tropism switch. Since gp36 ectodomain is a more 
conserved region [432], probably because of lower Nab pressure, in late disease stages Nabs 
are still able to recognise the epitopes present and hence are mainly directed to this region.  
 
Recent studies found that X4 tropic HIV-2 viruses isolated from patients with advanced 
disease are resistant to neutralization [97]. We also detected Nab resistance by X4 strains 
isolated from infants (Chapter 3). These findings strongly suggest an association between 
Nab escape and R5-to-X4 tropism switch. However, it remains to be determined if resistance 
to neutralization is an intrinsic characteristic of X4 tropic HIV-2 strains. Hence, the third 
objective of this work was to characterize the neutralization phenotype of an extended set 
of primary X4 isolates obtained from HIV-2 patients in diverse disease stages in order to 
establish if all X4 strains are resistant to Nabs regardless of disease stage. To address this 
problem we compared Nab sensitivity of X4 viruses from patients with recent infection 
(perinatally infected children) and with chronic infection in late stages the disease (CD4+ T 
cell counts < 350 cell/µl) in comparison with R5 variants from chronically infected individuals 
(Chapter 5). The results showed that X4 viruses are significantly more resistant to Nabs than 
R5 isolates independently of disease stage, confirming that neutralization resistance is an 
intrinsic characteristic of X4 tropic strains [97]. We also found significant differences 
between X4 variants from early and late infections, with viruses from chronically infected 
patients (late infection) being more resistant to Nabs compared to vertically infected 
children (early infection), suggesting that resistance to neutralization is a gradual process 
that occurs through infection. Analyses of the V3 sequences showed that all X4 strains were 
longer (by the insertion of 1 amino acid in position 24) and had a higher mean global net 
charge compared to R5 tropic viruses. Additionally, despite all X4 viruses sharing the amino 
acid changes that lead to tropism switch, the mean global net charge of the V3 region was 
lower in viruses from early infection compared to late infection. By homology modelling it 




was shown that R5 strains from early (Chapter 3) and chronic infections [97] are 
characterized by the absence of a regular secondary structure in the V3 loop. The secondary 
structure of the V3 region of X4 tropic strains from early infection is composed of a β-hairpin 
(Chapter 3) and X4 viruses from chronically infected individuals have a very regular 
secondary structure characterized by either a β-α-β motif or a helix-loop-helix conformation 
[97]. Taken together these findings suggest that amino acid mutations in V3 region have a 
major impact in the secondary structure and conformation of this region. Furthermore, 
these changes most likely prevent antibody recognition leading to Nab escape. Following all 
these transitions in V3 conformation, we proposed a model of V3 evolution as a 
consequence of Nab pressure, in which as disease progresses and Nabs exert pressure over 
this region, it acquires an increasingly more rigid conformation, and this process changes the 
epitope making it unrecognisable to Nabs. As a consequence, X4 strains become resistant to 
antibodies directed to V3. This model fuscous exclusively on the V3 region and, although this 
region comprises the major determinants for coreceptor usage, changes in other regions 
might also influence coreceptor switch as seen in HIV-1 infection where changes the 
glycosylation pattern and length of the V1/V2 loop have been associated with differences in 
coreceptor phenotype [106, 107]. The role of changes in length and glycosylation pattern of 
V1/V2 region in coreceptor usage during HIV-2 infection is still elusive [84] and further 
studies are needed before discarding the influence of other regions in tropism switch. 
Another important finding was the confirmation that Nab escape occurs in advanced stages 
of HIV-2 infection. Previous authors failed to detect the presence of Nab escape mutants 
[180] or found that these were not predominant in the individuals’ viral population [109], 
however these studies, contrarily to ours, did not include patients in more advanced disease 
stages infected predominantly with X4 tropic viruses. To definitely prove that HIV-2 X4 
variants are intrinsically resistant to neutralization it is necessary to revert X4 tropic strains 
into R5 variants by directed mutagenesis and evaluate if Nab resistance is lost. Using the 
same approach, converting R5 into X4 strains should increase resistance to neutralization by 





In conclusion, these studies have shown that Nab responses emerge very early in HIV-2 
infection, persist through infection despite memory B cell imbalances, and drive the viral 
molecular evolution, structural changes in V3 and tropism switch that ultimately leads to 
resistance to neutralization. The results from this work provide new and potentially 
important information for the HIV vaccine field. First, and most importantly, Nab escape 
exists in HIV-2 infection, in association with X4 tropism, and therefore a vaccine most likely 
needs to elicit responses against both R5 and X4 strains. Nabs seem to target mainly the V3 
region in the early and chronic phases of HIV-2 infection. In late stages of the disease 
response against the V3 region is weaker but Nabs targeting the gp36 arise. Taken together 
these results confirm that V3 is a good immunogen for vaccine design but highlight the fact 
that gp36 contains important epitopes to include in a vaccine. Another important finding 
was that a sustained Nab response is possible to be maintained by B cell populations other 
than the memory B cell subset. The frequency of memory B cells is directly associated with 
the levels of protective antibodies against the majority of viral infections [415]. However, in 
infections with viruses capable of maintaining latent reservoirs, such as varicella-zoster virus 
or Epstein-Barr virus, antibody levels do not correlate with the frequency of memory B cells 
[415]. Most likely, with HIV, because it also maintains latent reservoirs, memory B cells are a 
poor predictor of antibody levels. Consistent with this, strong and potent Nabs persist in 
HIV-2 infection despite memory B cell depletion. Our results show that other B cell subsets 
can maintain the antibody response needed for vaccination. The fact that, in HIV-1 infected 
individuals, plasmablasts are responsible for the production of elevated levels of IgGs, is in 
agreement with this line of thinking. Therefore, a vaccine against both HIV-1 and HIV-2 
would ideally stimulate responses from plasmablasts and/or long lived plasma cells. The 
difficult part is finding the right immunogen or group of immunogens that will elicit these 
responses. From our studies, immunogens based on HIV-2 V3 region in association with gp36 
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